EP1019399A1 - Aryl thiophene derivatives as pde iv inhibitors - Google Patents

Aryl thiophene derivatives as pde iv inhibitors

Info

Publication number
EP1019399A1
EP1019399A1 EP98946190A EP98946190A EP1019399A1 EP 1019399 A1 EP1019399 A1 EP 1019399A1 EP 98946190 A EP98946190 A EP 98946190A EP 98946190 A EP98946190 A EP 98946190A EP 1019399 A1 EP1019399 A1 EP 1019399A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
3alkyl
hydrogen
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98946190A
Other languages
German (de)
French (fr)
Inventor
Yongxin Han
Dwight Macdonald
Andre Giroux
Robert N. Young
Helene Perrier
Carole Lepine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9808109.4A external-priority patent/GB9808109D0/en
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Publication of EP1019399A1 publication Critical patent/EP1019399A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • This invention relates to compounds and pharmaceutical compositions for the treatment of diseases by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV).
  • cAMP cyclic adenosine-3',5'-monophosphate
  • PDE IV phosphodiesterase IV
  • cAMP 3', ⁇ '-cyclic adenosine monophosphate
  • the cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown.
  • the synthesis of cAMP is controlled by adenyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface receptors which are coupled to adenyl cyclase.
  • the breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine 3',5'- cyclic monophosphate (cGMP).
  • PDE phosphodiesterase
  • PDE I-VII the distribution of which varies from tissue to tissue. This suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues, [for reviews of PDE distribution, structure, function and regulation, see Beavo & Reifsnyder (1990) TIPS, 11: 150-155 and Nicholson et al (1991) TIPS, 19-27].
  • the availability of PDE isotype selective inhibitors has enabled the role of PDEs in a variety of cell types to be investigated. In particular it has been established that PDE IV controls the breakdown of cAMP in many inflammatory cells, for example, basophils (Peachell P.T. et al, (1992) J.
  • PDE IV inhibitors for the treatment of inflammatory diseases such as asthma, has met with limited success to date. Many of the PDE r inhibitors which have been synthesised have lacked potency and/or inhibit more than one type of PDE isoenzyme in a non-selective manner. PDE IV inhibitors that are relatively potent and selective for PDE IV, are reported to be emetic as well. Indeed this side effect has been so universal that experts have expressed their belief that the emesis experienced upon administration of a PDE IV inhibitor, may be mechanism based.
  • compounds according to the invention have good oral activity and at orally effective doses exhibit little or none of the side-effects associated with known PDE IV inhibitors, such as rolipram.
  • the compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma and other inflammatory conditions.
  • the invention encompasses novel compounds of Formula I useful in the treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP.
  • the invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
  • the invention encompasses the novel compound of Formula I useful in the treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP,
  • Ri is selected from: a) hydrogen, b) Cl-3alkyl, optionally substituted with -OH, or c) -X 1 -Y 1 -Ar 2 , wherein:
  • Xl is 1) -CH 2 -, or
  • Ar 2 is an aromatic ring selected from phenyl, naphthyl, pyrimidinyl, pyridinyl or thienyl, optionally substituted with up to two substituents chosen independently among:
  • R2 is selected from: a) hydrogen or b) Ci-3alkyl.
  • R3 is selected from phenyl, naphthyl, pyridinyl, furyl, thienyl, or ethinyl, optionally substituted with up to two substituents chosen independently among: a) Ci-3 alkyl, b) C ⁇ _3 fluoroalkyl, c) C ⁇ _6 alkoxy, d) Ci-3fluoroalkoxy, e) Ci-3alkylthio, f) halo, g) -OH, h) -N0 2 , i) -CH 2 OH, j) -NHCONR9R1°, k) -S(O) 2 NRllR 12 , 1) -SCH2(l,l-c-Pr)CH 2 CO 2 H, m) 1-piperazinyl, optionally substituted with Ci-3alkyl, n) 4-morpholinyl, or o)
  • Ar3 is phenyl, pyridinyl, pyrimidinyl or pyrazinyl, optionally substituted with up to two substituents chosen independently among:
  • Ci-3alkyl optionally substituted with -OH, or 2) -CH2CO2H.
  • R4 and R ⁇ are independently selected from: a) hydrogen, b) Ci_3alkyl, c) -S(0)2Ci-3alkyl, or d) -S(0)2phenyl, optionally mono-substituted with Ci-3alkyl,
  • Ci-3alkoxy, Ci-3alkylthio or halo are examples of compounds that are useful in the following abbreviations: Ci-3alkoxy, Ci-3alkylthio or halo.
  • R6 and R ⁇ are independently chosen from among: a) hydrogen, b ) C 1 _ 4 alkyl, c) -CO-C- ⁇ alkyl, or d) -CO-phenyl, optionally mono-substituted with C-, oalkyl,
  • Ci-3alkoxy, Ci-3alkylthio or halo R8 is chosen from among: a) hydrogen, or b) Cl- ⁇ alkyl;
  • R9 and ⁇ O are independently chosen from among: a)hydrogen, b) Ci-4alkyl, or c) phenyl;
  • RU and R ⁇ - 2 are independently chosen from among: a) hydrogen or b) Ci- ⁇ alkyl.
  • Ri is selected from : a) Cl-3alkyl, optionally substituted with -OH, or b) -X 1 -Y 1 -Ax ⁇ ;
  • R2 is hydrogen; and the remaining substituents are defined as in Formula I above.
  • Another preferred genus is that in which -Xl-Yl- is -CH2-S- and the remaining substituents are defined as in Formula I above.
  • Ar 2 is pyrimidinyl, optionally substituted with up to two substituents chosen independently among:
  • Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Cl-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) Cl-3alkoxy, c) Cl-3alkylthio, d) Cl-3alkylsulfinyl, e) Ci-3alkylsulfonyl, f) Ci-3_luoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -C0 2 Ci- 3 alkyl,
  • Rl is selected from: b) Ci-3alkyl, optionally substituted with -OH, or c) -X 1 -Y 1 -Ar2, wherein: X s D -CH2-, or
  • Ar2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among:
  • R 2 is selected from: a) hydrogen or R3 is selected from phenyl, naphthyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) C 1-3 alkyl, b) Ci-3fluoroalkyl, c) C 1-6 alkoxy, d) Ci-3fluoroalkoxy, e) C i-3 alky lthio, f) halo, g) -OH, h) -N0 2 , i) -CH 2 OH, j) -N ⁇ CONRSR 10 , k) -S(0) 2 NRllRl2,
  • Ar3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among:
  • R4 and R ⁇ are independently selected from: a) hydrogen, b) Ci-3alkyl, c) -S(0)2Cl-3alkyl, or
  • R6 and R ⁇ are independently chosen from among: a) hydrogen, b) C ⁇ alkyl, c) -CO-C- j ⁇ alkyl, or
  • R ⁇ is chosen from among: a) hydrogen, or b) Ci-5alkyl;
  • R9 and R ⁇ -0 are independently chosen from among: a)hydrogen, b) Ci_4alkyl, and RU and R ⁇ 2 are independently chosen from among: a) hydrogen or b) Ci-5alkyl.
  • Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Ci-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) C ⁇ _3alkoxy, c) Ci-3alkylthio, d) Ci_3alkylsulfinyl, e) C 1-3 alkylsulfonyl, f) Ci_3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -C02Ci-3alkyl,
  • Ri is selected from: b) C _3alkyl, optionally substituted with -OH, or c) -Xl-Yl-Ar2, wherein:
  • Xl-Yl is CH 2 S;
  • Ar2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among:
  • R 2 is hydrogen
  • R3 is selected from phenyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) Ci-3 alkyl, b) Ci-3 fluoroalkyl, c) C 1-6 alkoxy, d) Ci-3fluoroalkoxy, e) Ci-3alkylthio, f) halo, g) -OH, h) -N02, i) -CH OH, j) -NHCONR 9 R 10 , k) -X2-Y2-Ar3, wherein, X2 is 1) -CH2-, or
  • a ⁇ 3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among:
  • R4 and R ⁇ are independently selected from: a) hydrogen, b) Ci-3alkyl,
  • R6 and R ⁇ are independently chosen from among: a) hydrogen, b) C- ⁇ alkyl,
  • R8, R11 nd R ⁇ 2 are chosen from among: a) hydrogen, or b) Ci-5alkyl;
  • R9 and R ⁇ -O are independently chosen from among: a)hydrogen, b) Cl-4alkyl.
  • halo is intended to include F, Cl, Br, and I.
  • alkyl is defined to include straight, branched, and cyclic structures of the indicated number of carbon atoms.
  • Ci-6alkyl includes methyl, ethyl, propyl, i-propyl, s- and t-butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • alkoxy, alkylthio, alkylsulfinyl, and alkylsulfonyl mean the corresponding groups of the indicated number of carbon atoms of a straight, branched, or cyclic configuration. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyl oxy, and the like.
  • alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc.
  • the propylthio group signifies -SCH2CH2CH3.
  • Fluoroalkyl means an alkyl group of the indicated number of carbon atoms, of straight, branched or cyclic structure, in which one or more hydrogen atoms have been replaced by fluorine atoms; fluoroalkoxy, fluoroalkylthio, fluoroalkylsulfinyl, and fluoroalkylsulfonyl have the analogous meanings.
  • Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.
  • Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
  • the invention encompasses pharmaceutical compositions for treatment of disease by inhibition of PDE IV, as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.
  • compositions for treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.
  • a compound is said to selectively inhibit PDE IV in preference to other PDE's if the ratio of the IC50 concentration for all other PDE inhibition to PDE IV inhibition is 100 or greater.
  • compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N_-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. It will be understood that in the discussion of methods of treatment
  • Compounds according to the invention are selective and potent inhibitors of PDE IV.
  • the ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.
  • the compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm (for example bladder or alimentary smooth muscle spasm) is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.
  • an unwanted inflammatory response or muscular spasm for example bladder or alimentary smooth muscle spasm
  • the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.
  • Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, cystic fibrosis, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, diabetes Alzheimer's disease, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis and artherosclerosis.
  • Compounds of the invention also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.
  • Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, transplant rejection and graft versus host disease.
  • Compounds of the invention suppress cytokine synthesis by inflammatory cells in response to immune or infectious stimulation. They are, therefore, useful in the treatment of bacterial, fungal or viral induced sepsis and septic shock in which cytokines such as tumour necrosis factor (TNF) are key mediators. Also compounds of the invention suppress inflammation and pyrexia due to cytokines and are, therefore, useful in the treatment of inflammation and cytokine- mediated chronic tissue degeneration which occurs in diseases such as rheumatoid or osteo-arthritis.
  • cytokines such as tumour necrosis factor (TNF) are key mediators.
  • TNF tumour necrosis factor
  • cytokines such as TNF in bacterial, fungal or viral infections or in diseases such as cancer, leads to cachexia and muscle wasting.
  • Compounds of the invention ameliorate these symptoms with a consequent enhancement of quality of life.
  • Compounds of the invention also elevate cAMP in certain areas of the brain and thereby counteract depression and memory impairment.
  • Compounds of the invention suppress cell proliferation in certain tumour cells and can be used, therefore, to prevent tumour growth and invasion of normal tissues.
  • the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of Formula I together with one or more pharmaceutically acceptable carriers, excipients or diluents.
  • compounds of Formula I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non- toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • the compound of the invention is effective in the treatment of humans.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy- propylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • preservatives for example ethyl, or n- propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n- propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n- propyl, p-hydroxybenzoate
  • flavoring agents such as sucrose, saccharin or aspartame.
  • sweetening agents such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
  • Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
  • These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
  • the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed.
  • topical application shall include mouth washes and gargles.
  • Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above- indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day.
  • inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
  • the compounds of the present invention can be prepared by the methods described below. It will be apparent to one skilled in the art that similar methodology could be used to prepare the enantiomers or the racemates of the illustrated compounds.
  • Both Ar a and R a can be further (Mitsunobo reaction) modified to give derivatives
  • TBAF tetra-n-butylammonium fluoride
  • Example 26 A mixture of Example 26 (48mg), 4-chloropyridine (31mg) and K 2 CO 3 (45mg) in DMAC was heated to reflux for 3h and cooled to rt. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with brine dried over MgS0 4 , filtered and concentrated. The residue was purified by flash chromatography. Eluting with 4:1 ethyl acetate in hexanes afforded the title compound (36mg, 64% yield) as a white solid. ⁇ NMR: see Table 1.
  • Step 1 Preparation of Intermediate 2: To a solution of ethyl 4- bromobenzoate (2.29g, lOmmol) in DME (40mL) was added boronic acid 1 (2.37g, l ⁇ mmol), Pd(PPh 3 ) 4 (346mg, 0.3mmol) and Na 2 C0 3 (2M, 7.5mL) and the mixture was deoxygenated under a stream of N 2 for 5 min and then heated to 80° C for 50 min. After cooling to rt, the mixture was diluted with H 2 0 and extracted with ethyl acetate (3 x 50mL).
  • Step 2 Bromination to Intermediate 3: To a solution of intermediate 2 (2.7g, lOmmol) in THF (50mL) at 0°C was added NBS (3.56g, 20mmol) and water (5mL) and the mixture was stirred at 0°C for 30 min and quenched with excess 5% Na 2 S 2 0 3 aqueous solution. The mixture was then extracted with ethyl acetate (3 x 50mL) and the extracts combined, washed with water, brine, dried over Mg 2 S0 4 and filtered.
  • Step 3 Preparation of Intermediate 4: To a solution of bromide 3 (610mg, 1.79mmol) in DME (8mL) was added 3,4-dimethoxyphenylboronic acid (391mg, 2.15mmol) (see: Yokoe, I. et al, (1989) Chem. Pharm. Bull. 37, 529), Pd(PPh 3 ) 4 (62mg, 0.054mmol) and Na 2 C0 3 (lmL, 2M) and the mixture was deoxygenated under a stream of nitrogen for 5 min, heated to reflux for 4h, and then cooled to rt and diluted with water.
  • 3,4-dimethoxyphenylboronic acid 391mg, 2.15mmol
  • Step 4 Preparation of Intermediate 5: To a solution of compound 4 (461mg, l.l ⁇ mmol) in CH 2 C1 2 (6mL) at 0°C was added Br 2 PPh 3 (586mg, 1.39mmol) and the solution was allowed to warm to rt and stirred for 30 min under N 2 . Then to the solution was added 4,6-dimethyl-2- mercaptopyrimidine (325mg, 2.32mmol) and diisopropylethylamine (0.8mL) and the resultant solution was stirred at rt for lh and concentrated.
  • Br 2 PPh 3 586mg, 1.39mmol
  • Step 5 A mixture of compound 5 (213mg, 0.41 mmol) and LiOH (1.23mL, IM) in dioxane (5mL) was heated to 80°C for 2h and cooled to rt, diluted with water and acetic acid and then extracted with ethyl acetate. The extract was washed with water, brine, dried over MgSO 4 , filtered and concentrated. The crude was crystallized from ethyl acetate and hexanes to give the title compound as a white powdery solid (189mg, 94% yield). MP 238.8°C .
  • Step 1 Preparation of Intermediate 6: To a solution of bromide 3 (lllmg, 0.36mmol) dissolved in CH 2 C1 2 (2 mL) was added Br 2 PPh 3 (227mg, 0.54mmol) at 0°C and the mixture was stirred at 0°C under N 2 for lh. To the solution was added a solution of 4,6-dimethyl-2-mercaptopyrimidine in DMF (IM, 0.54mL) and diisopropylethylamine (93uL) and the mixture stirred at rt for 30 min, diluted with water and extracted with ethyl acetate. The extract was washed with brine, dried over MgS0 4 , filtered and concentrated.
  • IM 4,6-dimethyl-2-mercaptopyrimidine
  • 93uL diisopropylethylamine
  • Step 2 Preparation of Intermediate 5: Bromide 6 from above was reacted with 3,4-dimethoxyphenylboronic acid in a similar manner to that used to prepare compound 4, to yield compound 5.
  • Examples 27, 32, 34, 39, 42, 44, 49, 52, 54, 58, 59, 63, 73, 84, and 101 were prepared using technology similar to that described above.
  • Examples 38, 74, and 76 were prepared in a similar manner.
  • Step 1 One pot preparation of 4-trimethylsilylphenylboronic acid (see: Kaufmann et al, (1987) Chem. Ber. 120, 901): To a solution of p- dibromobenzene (11.8g, 50mmol) in THF (250mL) at -78°C was added n- BuLi (20mL, 2.5M in hexanes) over 2 min and the mixture was stirred at -78°C for 2 min. TMSC1 (6.3mL, 50mmol) was added in one portion and the resultant mixture was stirred at -78° C for 10 min.
  • Step 2 Preparation of Intermediate 10.
  • the boronic acid (4.96g, 25.5mmol) from Step 1 was reacted with 2-bromo-3- hydroxymethylthiophene (4.7g, 24.3mmol) (prepared from 3- thiophenemethanol with NBS in THF) under the standard Suzuki coupling conditions to yield intermediate 10 in 73% yield.
  • ⁇ H NMR 400MHz, acetone-d 6 ): ⁇ 7.62 (d, 2H), 7.54 (d, 2H), 7.39 (d, IH), 7.21 (d, IH), 4.62 (d, 2H), 4.17 (t, IH, OH), 0.29 (s, 9H).
  • Step 3 Preparation of Intermediate 11 Compound 10 (4.6g, 17.5mmol) in THF (80mL) was treated with NBS (6.25g) at rt for 2h and quenched with 10% Na 2 S 2 0 3 and then extracted with ethyl acetate. The extract was washed with water, brine, dried over MgS0 4 , filtered and concentrated. The residue was purified by flash chromatography (eluting with 20% ethyl acetate in hexanes) to furnish 5.42g (90% yield) of bromide 11.
  • Step 4 Preparation of Intermediate 12: Bromide 11 (2g, 5.86mmol) was reacted with 3,4-dimethoxyphenylboronic acid (1.28g, 7mmol) under the standard Suzuki coupling reaction conditions to afford intermediate 12 (2.2g, 94% yield) as a white solid.
  • Step 5 Preparation of Intermediate 13: Compound 12 (1.41g, 3.54mmol) was treated with a solution of IC1 (8.85mL, IM in CH 2 C1 2 ) at rt for lh and quenched with 10% Na 2 S 2 0 3 . The mixture was extracted with CH 2 C1 2 and the extract was concentrated. The residue was purified by flash chromatography (40% ethyl acetate, 10% CH 2 C1 2 in hexanes) to give iodide 13 (1.3g, 81% yield) as a light brown solid.
  • Step 6 Preparation of Intermediate 14: To a solution of iodide 13 (lg, 2.21mmol) in CH 2 C1 2 was added Br 2 PPh 3 (1.12g, 2.65mmol) and the mixture stirred at rt for 30 min. 4,6-Dimethyl-2-mercaptopyrimidine (619mg, 4.42mmol) and diisopropylethylamine (1.54mL) were introduced and the mixture was stirred at rt for lh, concentrated and the residue purified by flash chromatography (40% ethyl acetate in hexanes) to give compound 14 (1.28g, 100% yield) as a light yellow solid.
  • Step 7 To a solution of iodide 14 (68mg) and cyclobutanone (20 ⁇ L) in ether (2mL) and THF (2mL) cooled to -100°C was added n-BuLi (O.llmL) and the mixture was allowed to warm to -70°C, quenched with water and extracted with ethyl acetate. The extract was washed with brine, dried over MgS0 4 , filtered, concentrated and the crude was purified by flash chromatography (2:1 hexanes/ethyl acetate) to yield the title compound (52mg, 85% yield) as a white solid. ⁇ NMR: see Table 1.
  • Example 21 5-(3.4-Dimethoxyphenyl)-3-(4.6-dimethylpyrimidin-2- yl,thiomethyl-2-(4-methylthiophenyl)thiophene Step 1.
  • Preparation of Intermediate 7 A mixture of thioanisolyl-4- boronic acid (2.2g, 13mmol) (see: Santucci et al, (1958) J. Am. Chem. Soc.
  • Step 2 Preparation of Intermediate 8: The product from Step 1 was dissolved in 50mL of THF/1N HCl (4/1) and heated to reflux for 3h and cooled to rt. To the mixture was then added NBS (4.53g) and the resultant solution stirred at rt for 2h and quenched with 5% Na 2 S 2 O 3 and then extracted with ethyl acetate (3 x 50mL). The extracts were combined, washed with water, brine, dried over MgS0 4 , filtered and concentrated. The crude was purified by flash chromatography (5% ethanol in ethyl acetate) to yield 1.8g of sulfoxide 8.
  • Step 3 Preparation of Intermediate 9: To a solution of sulfoxide 8 (1.8g, 6mmol) in CH 2 C1 2 (40mL) was added Br 2 PPh 3 (5.08g, 12mmol) at rt and the mixture stirred at rt for lh. To the mixture was then added 4,6- dimethyl-2-mercaptopyrimidine (2.52g, 18mmol) and diisopropylethylamine (5.2mL, 30mmol) and the mixture stirred at rt for lh and concentrated. The residue was purified by flash chromatography to yield compound 9 as a white solid (2.3g, 88% yield).
  • Step 4 A mixture of 9 (700mg, 1.6mmol), 3,4-dimethoxyphenylboronic acid (350mg, 1.92mmol), Pd(PPh 3 ) 4 (55mg, 0.048mmol) and Na 2 C0 3 (lmL, 2M) in DME (5mL) was heated to reflux for 2h and worked up as usual.
  • Examples 4, 7, 15, 24, and 28 were prepared similarly by reacting intermediate 9 with the appropriate boronic acids and further modifications.
  • Step 1 Preparation of Intermediate 15: To a solution of compound 2 (4g) in THF (80mL) was added MeMgBr (51mL, 3M in THF) in THF (80mL) at 0°C under N 2 and the resulting mixture was stirred at that temperature for 1 h, quenched with IN HCl and extracted with ethyl acetate. The crude was purified by flash chromatography (2:1 hexanes/ethyl acetate) to give 3g (79%) of product 15.
  • Step 2 Preparation of Intermediate 16: Compound 15 (3.0g) was dissolved in THF (lOOmL) and cooled to 0°C. To the solution was added NBS (4.3g) and H 2 0 (lmL) and the mixture stirred at 0°C for lh, quenched with Na 2 S 2 0 3 and NaHC0 3 and extracted with ethyl acetate. The crude product was purified by flash chromatography (2:1 hexanes/ethyl acetate) to yield bromide 16.
  • Step 3 Preparation of Intermediate 17: To a solution of bromide 16 (2.6g) in THF (lOmL) and CH 2 C1 2 (lOmL) at 0°C was added MsCl (0.54mL) and diisopropylethylamine (1.33mL) and the mixture was stirred at 0°C for 2h. 4,6-Dimethyl-2-mercaptopyrimidine (1.36g) was added followed by diisopropylethylamine (3.63mL) and the mixture was stirred for an additional 15 min at 0°C and then at rt for 20 min.
  • Example 26 A mixture of the bromide 17 (983mg), 3-allyloxy- phenylboronic acid (623mg, prepared by reacting 3-bromophenol allyl ether with n-BuLi and triisopropylborate), Pd(PPh 3 ) 4 (81mg) and Na 2 C0 3 (2.3mL, 2M) in DME was deoxygenated under nitrogen and then heated to reflux overnight. The mixture was cooled to rt and worked up as usual.
  • Step 1 Preparation of 3-hydroxymethylthiophene-2-boronic acid (1): To a solution of 2-(dihydroxyboranyl)thiophene-3-carboxaldehyde (prepared from thiophene-3-carboxaldehyde dimethyl acetal by a modified literature procedure, see: Gronowitz, S. et al, (1967) Ada Chem. Scand. 21, 2151) (3.34g, 0.214mol) in ethanol (20mL) at 0°C under nitrogen was added NaBH 4 (0.81g, 0.21mol) in portions in 10 min. After stirring for 30 min at 0°C, the mixture was quenched with water and NH 4 C1 (sat'd aq.).
  • 2-(dihydroxyboranyl)thiophene-3-carboxaldehyde prepared from thiophene-3-carboxaldehyde dimethyl acetal by a modified literature procedure, see: Gronowitz, S. et al, (1967) Ada Chem
  • Step 2 Preparation of Resin B: Reaction of 1 with polymer bound (Wang resin) 4-bromobenzoate (resin A): To a suspension of the resin (6.16g, 5.3 mmol, 0.86mmol g loading) in DME (30mL) was added boronic acid 1 (1.67g, 10.6mmol), Pd(PPh 3 ) 4 (184mg, O.l ⁇ mmol) and Na 2 C0 3 (2M solution, 5.3mL) and the mixture was deoxygenated under a stream of nitrogen for 5 min under gentle stirring and then heated to 85° C under nitrogen overnight. The mixture was filtered when hot and the resin washed sequentially with DMF (3x), DMF/H 2 0 (3x), DMF (2x), THF (2x) and then MeOH (3x) and dried under nitrogen flow for 48 h to yield resin B.
  • boronic acid 1 (1.67g, 10.6mmol
  • Pd(PPh 3 ) 4 184mg, O.l
  • Step 3 Preparation of Resin C: Resin B was suspended in 60mL of THF and cooled to 0°C. NBS (1.9g, 10.6mmol) was added followed by lmL H 2 O and the mixture was allowed to warm to rt for 11/2 h and filtered. The resin was then washed with THF (3x), DMF (3x), THF (2x) and MeOH (3x) and dried under nitrogen and then under vacuum to give resin C.
  • NBS 1.9g, 10.6mmol
  • Step 4 Preparation of 3-Cyclopentyloxy-4-methoxyphenylboronic acid: To a solution of 4-bromo-2-cyclopentyloxy-l-methoxybenzene (3.4g, 12.5mmol) (see: Meyer, A. I. et al, (1993) J. Org. Chem. 58, 36) in THF (60mL) at -78°C was added n-BuLi (5.2mL, 2.4M in hexanes) over 2 min and the resultant solution stirred at -78°C for 5 min.
  • Step 6 Preparation of Resin E: Converting CH 2 OH to CH 2 Br: To a suspension of resin D (2.9g) in dichloromethane (30mL) under N 2 at 0°C was added Br 2 PPh 3 (1.5g, 3.48mmol) and the mixture was allowed to warm to rt with gentle stirring and then filtered. The residual resin was washed with CH 2 C1 2 (3x), THF (3x), ethyl acetate (2x) and ether (3x), and dried under reduced pressure to give resin E.
  • Step 7 To a suspension of resin E (50mg) in DMF (0.5mL) in a 5-mL fritted polypropylene tube equipped with a TeflonTM stopcock was added a solution of 4,6-dimethyl-2-mercaptopyrimidine in DMF( 200 ⁇ L, IM) and diisopropylethylamine (50 ⁇ L) and the mixture was shaken for 1 h at rt. The solvent was drained and the residue washed with DMF (3x), THF (3x), MeOH (3x ) and CH 2 C1 2 (3x) and the resultant resin was then treated with lmL 20%TFA in CH 2 C1 2 (containing 5% dimethyl sulfide) for 30 min. The liquid was drained to a round bottom
  • Examples 27, 82, 83, 86, 94, 95, 96, 97, 100, 102, 103, 104, 108, 114, 115, and 116 were prepared similarly.
  • Examples 14, 40, 43, 48, 50, 78, 80, 81, 85, 87, 89, and 90 were synthesized from the corresponding polymer (Merrifield or Wang resins) bound bromides according to similar procedures as described for Example 35 except for the cleavage.
  • the Cleavage were carried out using MeMgBr (1.4M in THF/toluene, 20eq) in THF at room temperature for 2-12h and filtered through fritted polypropylene reservoirs. The filtrates were quenched with NH 4 C1 (saturated aq.) and extracted with ethyl acetate. The crude products were purified by preparative TLC.
  • Step 1 Preparation of boronic acid 18: To a solution of 3-trimethylsilyl- thiophene (1.56g) in THF (15mL) at -78°C was added a THF solution of LDA (pre-prepared from 1.68mL of diisopropylamine and 4.6mL 2.4M n- BuLi in THF) via a cannula and the resultant solution was stirred at - 78°C for 10 min, rt for 30 min and cooled to -78°C again.
  • LDA pre-prepared from 1.68mL of diisopropylamine and 4.6mL 2.4M n- BuLi in THF
  • Triisopropylborate (1.37mL) was added and stirring was continued for lh at -78° C and rt for 30 min. The mixture was then quenched with H 2 0 and partitioned between hexanes and H 2 0. The aqueous phase was acidified with acetic acid to pH ⁇ 5 and extracted with ethyl acetate (3x). The extracts were concentrated and the crude was recrystallized from acetone/H 2 0 to yield 18 (1.41g) as a white powder. ⁇ NMR (400MHz, acetone-d 6 ): 57.79 (m, 2H), 7.25 (bs, 2H), 0.25 (s, 9H).
  • Step 3 Preparation of Intermediate 20: A solution of 19 (470mg), NBS (550mg) and AcOH (lmL) in THF was heated to reflux for 2h and cooled to rt. The mixture was treated with aqueous Na 2 S 2 O 3 and extracted with ethyl acetate. The extract was concentrated and the crude purified by flash chromatography to give compound 20. ⁇ NMR (CDC1 3 , 400MHz): 58.05 (d, 2H), 7.53 (d, 2H), 7.18 (s, IH), 4.36 (q, 2H), 1.40 (t, 3H).
  • Step 4 A mixture of 20 (303mg), 3-cyclopentyloxy-4- methoxyphenylboronic acid (373mg), Pd(PPh 3 ) 4 (27mg) and Na 2 CO 3 (0.8mL, 2M) in DME (7mL) was deoxygenated under N 2 and heated to reflux for 5h and worked up as usual. Purification of the crude by flash chromatography failed to give compound 21 in its pure form. As a result, the fraction containing 21 (180mg) was dissolved in dioxane (lmL) and H 2 0 (lmL) containing LiOH monohydrate (46mg) and the mixture was heated to 70° C for 2h and cooled to rt.
  • Example 110 3-(3-Cvclopentyloxy-4-methoxy)benzyl-2-r4-(l-hydroxy-l- methylethyl)phenyl.-5-(3-pyridin-l-yl)thiophene
  • Step 1 Preparation of Resin F: A suspension of resin C (4.3g), lithium pyridine-3-trimethylboronate (1.81g) (see: Fischer et al, (1974) Reel Tra ⁇ .
  • Step 2 Preparation of Resin G: To a suspension of resin F (4.3g) in CH 2 C1 2 (30mL) was added Br 2 PPh 3 (2.18g) and the suspension was stirred at rt for lh and filtered. The residue was washed with CH 2 C1 2 (3x), DMF (3x), THF(2x), ethyl acetate (2x) and ether (2x), and then dried under reduced pressure to afford resin G. Step 3.
  • CHO-Kl cells stably expressing the prostacyclin receptor and grown under G418 selection as described previously (Y. Boie, et al. J. Biol. Chem.: 269, 12173-12178, 1994) were plated at a density of 1.75 x 10 6 cells/175cm 2 in a T-175 flask (Gibco, Burlington, VT) containing alpha MEM media; 10% heat inactivated fetal bovine serum (FBS); 1% (v/v) penicillin/streptomycin; 25 mM Hepes, pH 7.4; and 500 ⁇ g/ml G418 (complete media). The cells were placed in an incubator for 24 hr at 37°C and 5% C0 .
  • the cells were then washed with warmed sterile phosphate buffered saline (PBS) and incubated with 2 ⁇ g/ml DNA, and 9 ⁇ g/ml lipofectamine reagent in Opti-MEM for 7 hr. At 37°C and 5% C0 2 .
  • the incubation solution was diluted 1:2 with Opti-MEM containing 20% FBS and incubated overnight. Following the overnight incubation, the media was replaced by complete media containing 500 ⁇ g/ml hygromycin B. Colonies were identified and grown in T-175 flasks for further characterization.
  • the flasks were maintained in an incubator at 37°C with 5.0% C0 2 for 72 hr.
  • the media was changed and the cells were allowed to grow overnight.
  • the cells were washed and dissociated from the plate with PBS containing 0.5 mM EDTA.
  • Cellular cAMP content was measured by centrifuging the cell suspension at 150 g x 10 min. And resuspending the cells in a Hanks buffered salt solution at a density of 0.2 x 10 cells/ml.
  • the cells were preincubated at room temperature for 15 min. and then incubated with 10 ⁇ M prostaglandin I 2 (PGI 2 ) and the indicated compound for an additional 10 min.
  • Basal cAMP levels were determined by incubating the cells in 0.1% DMSO. The incubations were terminated by the addition of HCl (0.1 N final) and the cells measured for cAMP as described below.
  • Determinations of whole-cell cAMP content were performed by incubating 100 ⁇ l reconstituted rabbit anti-succinyl cAMP serum with 100 ⁇ l of the whole-cell reaction or known cAMP standard and 30 pmol of 125 I-cAMP TME in a ScintiStripTM well (300 ⁇ l final volume) at room temperature for 18 h. Total cpm (B 0 ) was determined in the absence of sample of cAMP standard. The reaction mixture was then aspirated out of the well, and the individual wells were counted in a Beckman LS 6000SC with the window open from 10-999 for 1 min.
  • %B/B 0 [(standard or sample cpm - non-specific cpm) / (B 0 cpm - non-specific cpm)] x 100.
  • Non-specific cpm were determined by incubating only the 125 I-cAMP TME with assay buffer (50 nM acetate; pH 5.8) in the ScintiStrip well. All determinations were performed in triplicate.
  • the most potent compounds according to the invention induced a concentration-dependent elevation of cAMP in neutrophils and/or eosinophils at concentrations of O.lnM to l ⁇ M.
  • Human Whole Blood Assay Fresh blood was collected in heparinized tubes by venipuncture from healthy volunteers. These subjects had no apparent inflammatory conditions and had not taken any NSAIDs for at least 4 days prior to blood collection. Five hundred ⁇ L aliquots of human blood were initially pre-incubated at 37°C with either 2 ⁇ L DMSO (vehicle) or 2 ⁇ L of a test compound at a final concentration of up to 100 ⁇ M.
  • LPS lipopolysaccharide
  • f-MLP n-formyl-Met-Leu-Phe
  • f-MLP n-formyl-Met-Leu-Phe
  • the blood was immediately centrifuged at 4°C for 10 min. at 3,300 rpms to obtain plasma.
  • a plasma aliquot was diluted in PBS and assayed for TNF- ⁇ using a commercial ELISA kit (Cistron).
  • An additional plasma aliquot was de-proteinized with methanol and the supernatant was assayed for LTB 4 using a commercial EIA kit (Cayman).
  • the instant compounds showed IC 50 values ranging from 1 nM to 5 ⁇ M.
  • Fresh blood was collected from healthy volunteers by venipuncture into tubes containing 0.13M sodium citrate as anticoagulant (final 10%v/v in blood).
  • the blood was diluted in equal parts with PBS and gently layered on top of one half volume histopaque (1.077 density) and was centrifuged at 1400 rpm for 35 min at room temperature. After centrifugation, a distinct layer of mononuclear cells (monocytes and lymphocytes) located between the blood and histopaque layers could be aspirated off using a transfer pipette.
  • the mononuclear cells were washed in calcium and magnesium free PBS.
  • the cell pellet was resuspended in RPMI 1640 (Gibco BRL) complete media (containing streptomycin/penicillin and HEPES buffer) at a cell density of 1 x 10 6 cells/ml.
  • RPMI 1640 Gibco BRL
  • DMSO fetal sulfate
  • test compound containing streptomycin/penicillin and HEPES buffer
  • DMSO fetal sulfate
  • test compound containing streptomycin/penicillin and HEPES buffer
  • the instant compounds showed IC 50 values ranging from 0.1 nM to 5 ⁇ M.
  • Guinea pigs 200 g are sensitized with a lOO ⁇ g/ml ovalbumin in an A1 2 0 3 suspension in physiological saline. Five hundred ⁇ l of this solution are injected mtraperitoneally and another 500 ⁇ l are injected in 6 ganglionic regions ( ⁇ 75 ⁇ l/ site). The animals are then housed for 4 to 6 weeks. Thirty minutes prior to the experimentation, the guinea pigs are treated with the test compound or vehicle and with mepyramine maleate, 1 mg/kg. The injection volume is 1 ml/kg of body weight.
  • test compound dissolved in 2 ul DMSO
  • substrate buffer containing [2,8- 3 H] adenosine 3',5'-cyclic phosphate (cAMP, 100 nM)
  • cAMP adenosine 3',5'-cyclic phosphate
  • EDTA 50 mM Tris, pH 7.5.
  • the reaction was initiated by the addition of 10 ⁇ l of human recombinant PDE-rV isozymes, either expressed and purified from sf9 cells, or from CHO-Kl cells (the amount was controlled so that ⁇ 10% product was formed in 10 min. at 30 °C).
  • the reaction was stopped after 10 min. by the addition of 1 mg of PDE-SPA beads (Amersham).
  • the product AMP generated was quantified on a Microbeta 96-well plate counter.
  • the signal in the absence of enzyme was defined as the background. 100% activity was defined as the signal detected in the presence of enzyme and DMSO with the background subtracted. Percentage of inhibition was calculated accordingly.
  • the IC50 value was approximated by the non-linear regression fitting of a ten point titration using the standard 4 parameter equation.
  • IC50 values were determined with 100 nM cAMP using the purified GST fusion protein of the human recombinant phosphodiesterase IVa (met-248) produced from a baculovirus/Sf-9 expression system. The instant compounds were shown to have IC 50 values of 0.01 to 1000 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention encompasses the novel compound of Formula (I) useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula (I).

Description

TITLE OF THE INVENTION
ARYL THIOPHENE DERIVATIVES AS PDE IV INHIBITORS
BACKGROUND OF THE INVENTION This invention relates to compounds and pharmaceutical compositions for the treatment of diseases by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV).
Many hormones and neurotransmitters modulate tissue function by elevating intra-cellular levels of 3', δ'-cyclic adenosine monophosphate (cAMP). The cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown. The synthesis of cAMP is controlled by adenyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface receptors which are coupled to adenyl cyclase. The breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine 3',5'- cyclic monophosphate (cGMP). To date, seven members of the family have been described (PDE I-VII) the distribution of which varies from tissue to tissue. This suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues, [for reviews of PDE distribution, structure, function and regulation, see Beavo & Reifsnyder (1990) TIPS, 11: 150-155 and Nicholson et al (1991) TIPS, 19-27]. The availability of PDE isotype selective inhibitors has enabled the role of PDEs in a variety of cell types to be investigated. In particular it has been established that PDE IV controls the breakdown of cAMP in many inflammatory cells, for example, basophils (Peachell P.T. et al, (1992) J. Immunol. 148 2503-2510) and eosinophils (Dent G. et al, (1991) Br. J. Pharmacol 103 1339-1346) and that inhibition of this isotype is associated with the inhibition of cell activation. Furthermore, elevation of cAMP in airway smooth muscle has a spasmolytic effect. Consequently PDE IV inhibitors are currently being developed as potential anti-inflammatory drugs particularly for the prophylaxis and treatment of asthma, by achieving both anti-inflammatory and bronchodilator effects.
The application of molecular cloning to the study of PDEs has revealed that for each isotype there may be one or more isoforms. For PDE IV, it is has been shown that there are four isoforms (A, B, C and D) each coded for by a separate gene in both rodents (Swinnen J.V. et al, (1989) Proc. Natl Acad. Sci. USA 86 5325-5329) and man (Bolger G. et al, (1993) Mol Cell Biol 13 6558-6571).
The existence of multiple PDE IVs raises the prospect of obtaining inhibitors that are selective for individual isoforms, thus increasing the specificity of action of such inhibitors. This assumes that the different PDE IV isoforms are functionally distinct. Indirect evidence in support of this comes from the selective distribution of these isoforms in different tissues (Swinnen et al, 1989; Bolger et al, 1993; Obernolte R. et al, (1993) Gene 129 239-247, ibid) and the high degree of sequence conservation amongst isoforms of different species.
To date full length cDNAs for human PDE IVA, B and D (Bolger et al, 1993 ibid; Obernolte et al, 1993 ibid; Mclaughlin M. et al, (1993) J. Biol Chem. 268 6470-6476) and rat PDE IVA, B and D (Davis R. et al, (1989) Proc. Natl. Acad. Sci. USA 86 3604-3608; Swinnen J.V. et al, (1991) J. Biol. Chem. 266 18370-18377), have been reported, enabling functional recombinant enzymes to be produced by expression of the cDNAs in an appropriate host cell. These cDNAs have been isolated by conventional hybridisation methods. However using this approach, only partial cDNAs for both human and rat PDE IVC have been obtained. (Bolger et al, ibid. 1993 and Swinnen et al, ibid. 1989 and International Patent Specification No. WO 91/16457.)
The design of PDE IV inhibitors for the treatment of inflammatory diseases such as asthma, has met with limited success to date. Many of the PDE r inhibitors which have been synthesised have lacked potency and/or inhibit more than one type of PDE isoenzyme in a non-selective manner. PDE IV inhibitors that are relatively potent and selective for PDE IV, are reported to be emetic as well. Indeed this side effect has been so universal that experts have expressed their belief that the emesis experienced upon administration of a PDE IV inhibitor, may be mechanism based.
We have now found a novel series of aryl thiophene derivatives, members of which compared to known structurally similar compounds are potent inhibitors of PDE IV at concentrations at which they have little or no inhibitory action on other PDE isoenzymes.. These compounds inhibit the human recombinant PDE IV enzyme and also elevate cAMP in isolated leukocytes. Certain compounds prevent inflammation in the lungs induced by carrageenan, platelet-activating factor (PAF), interleukin-5 (IL-5) or antigen challenge. These compounds also suppress the hyper-responsiveness of airway smooth muscle seen in inflamed lungs. Advantageously, compounds according to the invention have good oral activity and at orally effective doses exhibit little or none of the side-effects associated with known PDE IV inhibitors, such as rolipram. The compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma and other inflammatory conditions.
SUMMARY OF THE INVENTION The invention encompasses novel compounds of Formula I useful in the treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP.
The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I. DETAILED DESCRIPTION OF THE INVENTION
The invention encompasses the novel compound of Formula I useful in the treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP,
or a pharmaceutically acceptable salt thereof wherein:
Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Ci-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) Ci-3alkoxy, c) Cl-3alkylthio, d) Cl-3alkylsulfinyl, e) Ci_3alkylsulfonyl, f) Cl-3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -Cθ2Ci-3alkyl, k) -CH=CH-C(Me)2θH,
n) tetrazol-5-yl, or o) -CH=N-0-CH2C02H; Ri is selected from: a) hydrogen, b) Cl-3alkyl, optionally substituted with -OH, or c) -X1-Y1-Ar2, wherein:
Xl is 1) -CH2-, or
2) a bond; Y1 is 1) -O- 2) -S-,
3) -NR8-, or
4) a bond;
Ar2 is an aromatic ring selected from phenyl, naphthyl, pyrimidinyl, pyridinyl or thienyl, optionally substituted with up to two substituents chosen independently among:
1) Ci-βalkyl,
2) Ci-βalkoxy,
3) -OH,
4) halo, or 5) CF3;
R2 is selected from: a) hydrogen or b) Ci-3alkyl. R3 is selected from phenyl, naphthyl, pyridinyl, furyl, thienyl, or ethinyl, optionally substituted with up to two substituents chosen independently among: a) Ci-3 alkyl, b) Cχ_3 fluoroalkyl, c) C ι_6 alkoxy, d) Ci-3fluoroalkoxy, e) Ci-3alkylthio, f) halo, g) -OH, h) -N02, i) -CH2OH, j) -NHCONR9R1°, k) -S(O)2NRllR12, 1) -SCH2(l,l-c-Pr)CH2CO2H, m) 1-piperazinyl, optionally substituted with Ci-3alkyl, n) 4-morpholinyl, or o) -X2-Y2-Ar3 , wherein, X2 is 1) -CH2-,
2) -C(=NOH)-, or
3) a bond; Y2 is 1) -0-,
2) -S-, or 3) a bond;
Ar3 is phenyl, pyridinyl, pyrimidinyl or pyrazinyl, optionally substituted with up to two substituents chosen independently among:
1) Ci-3alkyl, optionally substituted with -OH, or 2) -CH2CO2H.
R4 and R^ are independently selected from: a) hydrogen, b) Ci_3alkyl, c) -S(0)2Ci-3alkyl, or d) -S(0)2phenyl, optionally mono-substituted with Ci-3alkyl,
Ci-3alkoxy, Ci-3alkylthio or halo.
R6 and R^ are independently chosen from among: a) hydrogen, b) C1_4alkyl, c) -CO-C-^alkyl, or d) -CO-phenyl, optionally mono-substituted with C-, oalkyl,
Ci-3alkoxy, Ci-3alkylthio or halo; R8 is chosen from among: a) hydrogen, or b) Cl-δalkyl;
R9 and ^O are independently chosen from among: a)hydrogen, b) Ci-4alkyl, or c) phenyl; and
RU and R^-2 are independently chosen from among: a) hydrogen or b) Ci-δalkyl.
Within this embodiment there is a preferred genus of compounds wherein
Ri is selected from : a) Cl-3alkyl, optionally substituted with -OH, or b) -X1-Y1-Ax^;
R2 is hydrogen; and the remaining substituents are defined as in Formula I above.
Another preferred genus is that in which -Xl-Yl- is -CH2-S- and the remaining substituents are defined as in Formula I above.
Another preferred genus is that in which Ar2 is pyrimidinyl, optionally substituted with up to two substituents chosen independently among:
1) Ci-βalkyl,
2) Ci-6alkoxy,
3) -OH, or 4) halo.
Still another preferred genus is realized when: Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Cl-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) Cl-3alkoxy, c) Cl-3alkylthio, d) Cl-3alkylsulfinyl, e) Ci-3alkylsulfonyl, f) Ci-3_luoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -C02Ci-3alkyl,
Rl is selected from: b) Ci-3alkyl, optionally substituted with -OH, or c) -X1-Y1-Ar2, wherein: X s D -CH2-, or
2) a bond; Yl is 1) -O-
2) -S-,
3) -NR8-, or 4) a bond;
Ar2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among:
1) Cl-βalkyl,
2) Cl-6alkoxy, 3) -OH, or
4) halo,
R2 is selected from: a) hydrogen or R3 is selected from phenyl, naphthyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) C 1-3 alkyl, b) Ci-3fluoroalkyl, c) C 1-6 alkoxy, d) Ci-3fluoroalkoxy, e) C i-3 alky lthio, f) halo, g) -OH, h) -N02, i) -CH2OH, j) -NΉCONRSR10, k) -S(0)2NRllRl2,
1) -SCH2(l,l-c-Pr)CH2C02H or m) -X2-Y2-Ar3, wherein, 2) -C(=NOH)- or
3) a bond; Y2 is 1) -O-,
2) -S-, or
3) a bond; Ar3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among:
1) Cl-3alkyl, optionally substituted with -OH, or
2) -CH2CO2H.
R4 and R^ are independently selected from: a) hydrogen, b) Ci-3alkyl, c) -S(0)2Cl-3alkyl, or
R6 and R^ are independently chosen from among: a) hydrogen, b) C^alkyl, c) -CO-C-j^alkyl, or
R^ is chosen from among: a) hydrogen, or b) Ci-5alkyl;
R9 and R^-0 are independently chosen from among: a)hydrogen, b) Ci_4alkyl, and RU and R^2 are independently chosen from among: a) hydrogen or b) Ci-5alkyl.
Yet another preferred genus is realized when: Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Ci-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) Cι_3alkoxy, c) Ci-3alkylthio, d) Ci_3alkylsulfinyl, e) C 1-3 alkylsulfonyl, f) Ci_3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -C02Ci-3alkyl,
Ri is selected from: b) C _3alkyl, optionally substituted with -OH, or c) -Xl-Yl-Ar2, wherein:
Xl-Yl is CH2S; Ar2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among:
1) Ci-βalkyl, 2) Ci-6alkoxy,
3) -OH, or
4) halo,
R2 is hydrogen;
R3 is selected from phenyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) Ci-3 alkyl, b) Ci-3 fluoroalkyl, c) C 1-6 alkoxy, d) Ci-3fluoroalkoxy, e) Ci-3alkylthio, f) halo, g) -OH, h) -N02, i) -CH OH, j) -NHCONR9R10, k) -X2-Y2-Ar3, wherein, X2 is 1) -CH2-, or
2) a bond; Y2 is 1) -0-,
2) -S-, or
3) a bond;
Aχ3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among:
1) Cl-3alkyl, optionally substituted with -OH, or
2) -CH2CO2H. R4 and R^ are independently selected from: a) hydrogen, b) Ci-3alkyl,
R6 and R^ are independently chosen from among: a) hydrogen, b) C-^alkyl,
R8, R11 nd R^2 are chosen from among: a) hydrogen, or b) Ci-5alkyl; and
R9 and R^-O are independently chosen from among: a)hydrogen, b) Cl-4alkyl.
As appreciated by those of skill in the art, halo is intended to include F, Cl, Br, and I.
For purposes of this specification alkyl is defined to include straight, branched, and cyclic structures of the indicated number of carbon atoms. By way of example, Ci-6alkyl includes methyl, ethyl, propyl, i-propyl, s- and t-butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Similarly, alkoxy, alkylthio, alkylsulfinyl, and alkylsulfonyl mean the corresponding groups of the indicated number of carbon atoms of a straight, branched, or cyclic configuration. Examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyl oxy, and the like.
Examples of alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH2CH2CH3. Fluoroalkyl means an alkyl group of the indicated number of carbon atoms, of straight, branched or cyclic structure, in which one or more hydrogen atoms have been replaced by fluorine atoms; fluoroalkoxy, fluoroalkylthio, fluoroalkylsulfinyl, and fluoroalkylsulfonyl have the analogous meanings.
Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof. Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
In a second embodiment, the invention encompasses pharmaceutical compositions for treatment of disease by inhibition of PDE IV, as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.
Within this embodiment the invention encompasses pharmaceutical compositions for treatment of disease by inhibition of PDE IV, resulting in an elevation of cAMP, as disclosed herein comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.
For purposes of this specification a compound is said to selectively inhibit PDE IV in preference to other PDE's if the ratio of the IC50 concentration for all other PDE inhibition to PDE IV inhibition is 100 or greater.
The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N_-dibenzylethylenediamine, diethylamine, 2- diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.
Compounds according to the invention are selective and potent inhibitors of PDE IV. The ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.
The compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm (for example bladder or alimentary smooth muscle spasm) is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.
Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, cystic fibrosis, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, diabetes Alzheimer's disease, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis and artherosclerosis.
Compounds of the invention also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.
Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, transplant rejection and graft versus host disease.
Compounds of the invention suppress cytokine synthesis by inflammatory cells in response to immune or infectious stimulation. They are, therefore, useful in the treatment of bacterial, fungal or viral induced sepsis and septic shock in which cytokines such as tumour necrosis factor (TNF) are key mediators. Also compounds of the invention suppress inflammation and pyrexia due to cytokines and are, therefore, useful in the treatment of inflammation and cytokine- mediated chronic tissue degeneration which occurs in diseases such as rheumatoid or osteo-arthritis.
Over-production of cytokines such as TNF in bacterial, fungal or viral infections or in diseases such as cancer, leads to cachexia and muscle wasting. Compounds of the invention ameliorate these symptoms with a consequent enhancement of quality of life.
Compounds of the invention also elevate cAMP in certain areas of the brain and thereby counteract depression and memory impairment.
Compounds of the invention suppress cell proliferation in certain tumour cells and can be used, therefore, to prevent tumour growth and invasion of normal tissues.
For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of Formula I together with one or more pharmaceutically acceptable carriers, excipients or diluents.
For the treatment of any of these, compounds of Formula I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non- toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy- propylmethycellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n- propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non- irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above- indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Exemplifying the invention are:
Example 1
Proton NMR (acetone-d6): 7.66 (d, 4H), 7.55 (d, 4H), 7.41 (s, 2H), 6.90 (s, 2H), 4.46 (s, 4H), 4.39 (s, 2H), 2.35 (s, 12H),1.56 (s, 12H).
Example 2
•Proton NMR (acetone-d6): 8.42 (d, IH), 7.75 (dd, IH), 7.64 (d, 2H), 7.54 (d, 2H), 7.41 (s, IH), 6.88 (s, IH), 6.80 (d, IH), 4.46 (s, 2H), 2.24 (s, 3H), 1.55 (s, 3H).
Example 3
'Proton NMR (acetone-d6): 8.47(dd, 2H), 7.67-7.64 (m, 4H), 7.59-7.52 (m, 5H), 7.45 (t, IH), 7.10 (dd, IH), 6.95 (dd, 2H), 6.87 (s, IH), 4.47 (s, 2H), 4.14 (s, IH), 2.30 (s, 6H), 1.55 (s, 6H).
Example 4
'Proton NMR (acetone-d6): 8.47(dd, 2H), 7.67-7.64 (m, 4H), 7.59-7.52 (m, 5H), 7.45 (t, IH), 7.10 (dd, IH), 6.95 (dd, 2H), 6.87 (s, IH), 4.47 (s, 2H), 4.14 (s, IH), 2.30 (s, 6H), 1.55 (s, 6H).
Example 5
'Proton NMR (CDC13): 9.85 (bs, 2H), 7.50-7.47 (m, 4H), 7.31 (s, IH), 7.28 (d, IH), 6.90 (d, 2H), 6.69 (s, IH), 4.42 (s, 2H), 3.45 (bs, 4H), 3.34 (bs, 4H), 2.50 (s, 3H), 2.37 (s, 6H).
Example 6
'Proton NMR (acetone-d6): 7.66 (d, 2H), 7.56-7.50 (m, 5H), 7.24 (d, 2H), 7.07 (d, 2H), 6.97 (d, 2H), 6.89 (s, IH), 5.12 (s, 2H), 4.44 (s, 2H), 3.85 (s, 3H), 3.53 (s, 2H), 2.34 (s, 6H).
Example 7
•Proton NMR (acetone-d6): 8.72 (d, IH), 7.84 (dd, IH), 7.59 (s, IH), 7.55 (d, 2H), 7.37 (d, 2H), 7.24 (d, IH), 6.87 (s, IH), 4.45 (s, 2H), 2.52 (s, 3H), 2.48 (s, 3H), 2.32 (s, 6H).
Example 8
'M.P.: 238.8°C (decomposed)
Example 9
'Proton NMR (acetone-d6): 8.48 (d, IH), 8.12 (d, IH), 7.90 (dd, IH), 7.89 (s, IH), 7.66 (d, 2H), 7.55 (d, 2H), 7.54 (s, IH), 6.88 (s, IH), 4.47 (s, 2H), 4.18 (s, IH), 3.49 (q, 4H), 2.32 (s, 6H), 1.55 (s, IH), 3.49 (q, 4H), 2.32 (s, 6H), 1.55 (s, 6H), ...
Example 10
'Proton NMR (acetone-d6): 8.48 (d, IH), 8.33 (d, IH), 8.41 (d, IH), 7.65 (m, 3H), 7.57-7.47 (m, 5H), 7.15 (dd, IH), 6.87 (s, IH), 4.47 (s, IH), 4.11 (s, IH), 2.31 (s, 6H), 1.55 (s, 6H).
Example 11
Proton NMR (acetone-d6):7.58 (d, IH), 7.47 (s, IH), 7.37 (dd, 1H0, 7.35 (s, 1H),7.22 (d, 2H), 7.18 (dd, IH), 6.97 (d, IH), 6.89 (s, 1H)4.46 (s, 2H), 4.09 (s, IH, OH), 3.88 (s, 3H), 3.83 (s, 3H), 2.61 (s, 3H), 2.34 (s, 6H), 1.623 (s, 6H). Example 12
Proton NMR (acetone-d6):11.21 (s, IH), 8.61 (dd, IH), 8.68 (dd, IH), 8.64 (dd, IH), 7.94 (m, IH), 7.71-7.56 (m, 6H), 7.49 (d, 2H), 7.46 (m, IH), 6.89 (s, IH), 4.48 (s, 2H), 4.17 (s, IH), 2.33 (s, 6H), 1.58 (s, 6H).
Example 13
m.p.: 71.5°C
Example 14
Proton NMR (acetone-d6)7.47 (s, IH), 7.20 (d, IH), 7.15 (dd, IH), 7.13 (d, lH),6.98-6.96 (m, 2H), 6.90 (s, IH), 4.54 (s, 2H), 3.88 (s, 3H),3.82 (s, 3H), 2.36 (s, 6H), 1.62 (s, 6H).
'Proton NMR (acetone-d6): 8.88 (dd, IH), 8.50 (dd, IH), 8.02 (ddd, IH), 7.68 (s, IH), 7.58 (d, 2H), 7.41 (m, IH), 7.40 (d, 2H), 6.90 (s, IH), 4.48 (s, 2H), 2.55 (s, 3H), 2.34 (s, 6H). Example 16
Proton NMR (acetone-d6):8.68 (dd, IH), 7.82 (dd, IH), 7.50 (s, IH), 7.36 (d, IH), 7.23 (d, IH), 7.18 (dd, IH), 6.98 (m, IH), 6.89 (s, IH), 4.45 (s, 2H), 3.89 (s, 3H), 3.83 (s, 3H), 2.58 (s, 3H), 2.34 (s, 6H)
Example 17
Proton NMR (acetone-d6:8.42 (dd, IH), 7.75 (dd, IH), 7.65 (d, 2H), 7.54 (d,
2H), 7.42 (d, IH), 6.89 (s, IH), 6.80 (d, IH), 4.46 (s, 2H),3.59 (t, 4H), 2.93 (t,
4H), 2.33 (s, 6H), 1.54 (s, 6H).
Example 18
Proton NMR (CDC13):7.61 (dd, 2H), 7.57 (dd, 2H), 7.35 (s, IH), 7.16 (dd, IH), 7.08 (d, IH), 6.86 (d, IH), 6.69 (s, IH), 4.47 (s, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 2.63-2.56 (m, 2H), 2.44-2.36 (m, 2H), 2.38 (s, 6H), 2.08 (s, IH), 2.07-2.04 (m, IH), 1.76-1.73 (m,.lH)
Example 19
Proton NMR (acetone-d6):7.57 (d, 2H), 7.55 (d, 2H), 7.54 (s, IH), 7.37 (d, 2H), 7.06 (d, 2H), 6.88 (s, IH), 4.43 (s, 2H), 3.84 (s, 3H), 3.78 (s, 2H), 2.66 (s, 2H), 2.44 (s, 2H), 2.34 (s, 6H), 0.52 (dd, 2H), 0.45 (dd, 2H).
Example 20
Proton NMR (acetone-d6):8.45 (d, IH), 7.80 (dd, IH), 7.65 (dd, 2H), 7.55 (dd, 2H), 7.44 (s, IH), 6.90 (s, IH), 6.84 (s, IH), 4.47 (s, 2H), 3.74 (t, 4H), 3.53 (t, 4H), 2.34 (s, 6H), 1.55 (s, 6H). Example 21
•Proton NMR (acetone-d6): 7.55 (d, 2H), 7.49 (s, IH), 7.39 (d, 2H), 7.22 (d, IH), 7.18 (dd, IH), 6.98 (d, IH), 6.89 (s, IH), 4.45 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.53 (s, 3H), 2.34 (s, 6H).
Example 22
Proton NMR (acetone-d6):8.10 (d, 2H), 7.74 (d, 2H), 7.54 (d, 2H), 7.45 (s, IH), 6.97 (d, 2H), 6.89 (s, IH), 4.50 (s, 2H), 4.36 (q, 2H), 3.16 (dd, 4H), 2.93 (dd, 4H), 2.32 (s, 6H), 1.39 (t, 3H).
Example 23
Proton NMR (acetone-d6):8.87 (dd, IH), 8.28 (dd, IH), 8.05 (dd, IH), 7.56 (s, IH), 7.25 (d, IH), 7.19 (dd, IH), 6.98 (d, IH), 6.87 (s, IH), 4.48 (s, 2H), 3.38 (s, 3H), 3.83 (s, 3H), 2.81 (s, 3H), 2.29 (s, 3H).
Example 24
Proton NMR (CDC13):7.71 (d, 2H), 7.48-7.46 (m, 2H), 7.44 (s, IH), 7.43 (t, IH), 7.30 (d, 2H), 7.12 (d, IH), 6.74 (s, IH), 4.47 (s, IH), 3.33 (q, 4H), 2.50 (s, 3H), 2.43 (s, 6H), 1.02 (t, 6H).
Example 25
Proton NMR (CDC13):7.63 (d, 2H), 7.58 (d, 2H), 7.34 (s, IH), 7.16 (dd, IH), 7.09 (dd, IH), 6.85 (d, IH), 6.69 (s, IH), 4.45 (s, 2H), 4.31-4.21 (m, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 3.81 (s, IH), 2.37 (s, 6H), 1.80 (s, 3H), 1.28 (t, 3H).
Example 26
Proton NMR (acetone-d6):8.48 (s, IH), 7.65 (d, 2H), 7.55 (d, 2H), 7.53 (s, IH), 7.24 (t, IH), 7.15-7.11 (m, 2H), 6.90 (s, 1H),6.80 (dd, IH), 4.47 (s, 2H), 4.04 (s, IH), 2.34 (s, 6H) 1.55 (s, 6H).
Example 27
M.P.: 187.7°C (decomposed)
Example 28
Proton nMR (acetone-d6):8.45 (t, IH), 8.16 (ddd, IH), 8.08 (ddd, IH), 7.83 (s, 1H),7.72 (t, IH), 7.59 (d, 2H), 7.42 (d, 2H), 4.49 (s, 2H),2.55 (s, 3H), 2.35 (s, 6H).
Example 29
Cl
Proton NMR (acetone-d6):8.69 (dd, IH), 7.84 (dd, IH), 7.66 (d, 2H), 7.58 (s, IH), 7.56 (d, 2H), 7.31 (d, IH), 4.48 (s, 2H), 4.09 (s, IH), 2.33 (s, 6H), 2.13- 2.04 (m, IH), 1.55 (s, 6H), 1.10-0.97 (m, 4H).
Example 30
Proton NMR (CDC13):10.88 (s, IH), 8.05 (dd, IH), 7.69 (dd, IH), 7.32 (s, IH), 7.13 (dd, IH), 7.08 (d, IH), 7.02 (d, IH), 6.88 (d, IH), 6.69 (s, IH), 4.40 (q, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 2.37 (s, 6H), 1.38 (t, 3H). Example 31
Proton NMR (CDC13): 8.83 (d, IH), 8.49 (dd, IH), 7.82 (dd, IH), 7.51 (s, IH), 7.28 (dd, IH), 6.67 (s, IH), 4.47 (s, 2H), 2.38 (s, 6H),1.62 (s, 6H).
Example 32
Proton NMR (CDC13):8.29 (m, IH), 8.18 (d, 2H), 7.89-7.84 (m, 2H), 7.76 (d, 2H), 7.58 (d, IH), 7.52-7.46 (m, 3H), 7.40 (s, 1H),6.70 (s, IH), 4.55 (s,
2H), 2.36 (s, 6H).
Example 33
Proton NMR (CDC13):7.64 (d, 2H), 7.54 (d, 2H), 7.30 (s, IH), 7.10 (dd, IH), 7.05 (d, IH), 6.85 (d, IH), 6.67 (s, IH), 4.43 (s, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 3.69 (s, IH), 2.35 (s, 6H), 1.84 (s, 3H).
Example 34
Proton NMR (acetone-d6):8.15 (d, 2H), 7.78 (d, 2H), 7.68 (d, 2H), 7.63 (s, 1H),7.42 (t, 2H), 7.32 (t, IH), 6.88 (s, IH), 4.53 (s, 2H),2.32 (s, 6H).
Example 35
Proton NMR (acetone-d6):11.30 (bs, IH), 8.14 (d, 2H), 7.76 (d, 2H), 7.51 (s, 1H),7.23-7.18 (m, 2H), 6.99 (d, IH), 6.90 (s, IH), 4.90 (m, IH), 4.50 (s, 2H), 3.82 (s, 3H), 2.32 (s, 6H), 1.95-1.60 (m, 8H).
Example 36
Proton NMR (CDC13):8.80 (dd, IH), 8.48 (dd, IH), 7.83 (dd, IH), 7.60 (dd, 2H), 7.57 (dd, 2H), 7.50 (s, IH), 7.29 (dd, IH), 6.71 (s, IH), 4.47 (s, 2H), 2.64- 2.57 (m, 2H), 2.45-2.40 (m, 3H), 2.39 (s, 6H), 2.07-2.04 (m, IH), 1.75-1.70 (m, IH) . Example 37
Proton NMR (acetone-d6):10.81 (s, IH), 8.48 (dd, IH), 7.93 (dd, IH), 7.80 (m, IH), 7.71 (d, 2H), 7.65 (d, 2H), 7.63 (s, IH), 7.57 (d, 2H), 7.48 (d, 2H), 7.33 (m, IH), 6.88 (s, IH), 4.50 (s, 2H), 4.15 (s, IH), 2.33 (s, 6H), 1.57 (s, 6H).
Example 38
M.P.: 152.7°C
Example 39
Proton NMR (CDC13):8.15 (d, 2H), 7.70 (d, 2H), 7.52 (s, IH), 7.47-7.45 (m, 2H),7.25 (m, IH), 6.70 (s, IH), 4.48 (s, 2H), 2.37 (s, 6H).
Example 40
Proton NMR:7.74 (d, IH), 7.46 (s, IH), 7.40 (dd, IH), 7.23 (d, IH),
7.18 (dd, IH), 7.08 (d, IH), 6.98 (d, IH), 6.95 (d, 1H)6.91 (s, IH), 6.40 (d, IH), 4.43 (s, 2H), 3.90 (s, 3H) 3.88 (s, 3H), 3.83 (s, 3H), 2.35 (s, 6H), 1.28 (s, 6H).
Example 41
Proton NMR (acetone-d6) 7.56 (d, 2H), 7.50 (d, 2H), 2H), 7.48 (s, IH), 7.23 (d, IH), 7.18 (dd, IH), 6.98 (d, IH), 6.90 (s, IH), 4.91 (m, 1H),4.45 (s, 2H), 4.25 (d, OH), 3.88 (s, 3H), 3.83 (s, 3H) 2.34 (s, 6H), 1.44 (d, 3H).
Example 42
Proton NMR (CDC13): 8.15 (d, 2H), 7.69 (d, 2H), 7.60 (m, IH), 7.43 (m, IH), 7.40 (s, IH), 7.14 (t, IH), 6.71 (s, IH), 4.46 (s, 2H), 2.37 (s, 6H).
Example 43
Proton NMR: (acetone-d6) 7.83 (dd, IH), 7.49 (s, IH), 7.48 (m, IH), 7.26-7.18 (m, 3H), 6.99 (d, H), 6.91 (s, IH), 6.82 (d, IH), 6.56 (d, IH), 4.43 (s, 2H), 3.88 (s, 3H) 3.83 (s, 3H), 2.34 (s, 6H), 1.26 (s, 6H).
Example 44
HRMS: 568.1398 (calc: 568.1400).
Example 45
Proton NMR (acetone-d6): 7.60 (d, 2H), 7.56 (d, 2H), 7.53 (s, IH), 7.39 (d, 2H), 7.04 (d, 2H), 6.89 (s, IH), 4.64 (d, 2H), 4.44 (s, 2H), 4.21 (t, IH), 3.85 (s, 3H), 2.35 (s, 6H).
Example 46
Proton NMR (acetone-d6/DMSO-d6): 7.92 (d, IH), 7.52 (s, IH), 7.25-7.16 (m, 4H), 7.00 (d, IH), 6.91 (s, IH), 4.52 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.36 (s, 6H).
Example 47
Proton NMR (acetone-d6): 7.80 (s, 4H), 7.51 (s, IH), 7.24 (d, IH), 7.20 (dd, IH), 6.98 (d, IH), 6.88 (s, IH), 4.48 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 2.75 (s, 3H), 2.32 (s, 6H).
Example 48
Proton NMR (acetone-d6): 7.52 (d, 2H), 7.47 (s, IH), 7.37 (d, IH), 7.23 (d, IH), 7.17 (dd, IH), 6.97 (d, IH), 6.89 (s, IH), 4.46 (s, 2H), 3.88 (s, 3H), 3.82 (s, 3H), 3.40 (s, IH, OH), 2.79 (s, 2H), 2.34 (s, 6H), 1.18 (s, 6H).
Example 49
HRMS: 439.0609 (calc: 439.0610).
Example 50
Proton NMR (acetone-d6): 8.74 (d, IH), 7.88 (dd, IH), 7.66 (d, 2H), 7.61 (s, IH), 7.56 (d, 2H), 7.27 (d, IH), 6.89 (s, IH), 4.49 (s, 2H), 4.10 (bs, IH, OH), 2.50 (s, 3H), 2.33 (s, 6H), 1.55 (s, 6H).
Example 51
Proton NMR (acetone-d6): 7.66 (d, 2H), 7.60 (d, 2H), 7.58 (s, IH), 7.50 (d, 2H), 7.48 (t, 2H), 7.30 (t, IH), 6.89 (s, IH), 4.70 (d, 2H), 4.47 (s, 2H), 4.31 (t, IH, OH), 2.34 (s, 6H).
Example 52
HRMS: 467.0655 (calc: 467.0654).
Example 53
Proton NMR (acetone-d6): 7.54 (d, 2H), 7.44 (s, IH), 7.21 (d, IH), 7.15 (dd, IH), 7.00 (d, 2H), 6.95 (d, IH), 6.87 (s, IH), 4.41 (s, 2H), 3.87 (s, 3H), 3.84 (s, 3H), 3.82 (s, 3H), 2.33 (s, 6H).
Example 54
Proton NMR (CDC13): 8.85 (s, IH), 8.50 (d, IH), 8.15 (d, 2H), 7.83 (dm, IH), 7.68 (d, 2H), 7.50 (s, IH), 7.30 (dd, IH), 6.65 (s, IH), 4.47 (s, 2H), 2.37 (s, 6H).
Example 55
Proton NMR (acetone-d6): 10.83 (s, IH, OH), 7.93 (d, IH), 7.52 (s, IH), 7.25-7.19 (m, 4H), 6.99 (d, IH), 6.90 (s, IH), 4.52 (s, 2H), 3.99 (s, 3H), 3.89 (s, 3H), 3.84 (s, 3H), 2.34 (s, 6H).
Example 56
Proton NMR (acetone-d6): 7.68 (d, 2H), 7.60 (d, 2H), 7.54 (d, 2H), 7.47 (s, IH), 4.50 (s, 2H), 3.83 (s, 3H), 3.02 (s, 6H), 2.33 (s, 6H).
Example 57
Proton NMR (acetone-d6): 8.00 (d, 2H), 7.80 (d, 2H), 7.53 (s, IH), 7.25 (d, IH), 7.21 (dd, IH), 7.00 (d, IH), 6.90 (s, IH), 6.64 (bs, 2H, NH2), 4.50 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 2.33 (s, 6H).
Example 58
Proton NMR (acetone-d6): 8.12 (d, 2H), 7.97 (bs, IH), 7.72 (d, 2H), 7.63 (m, IH), 7.40 (s, IH), 6.88 (s, IH), 6.79 (m, IH), 4.48 (s, 2H), 2.30 (s, 6H).
Example 59
HRMS: 479.0921 (calc: 479.0919).
'Proton NMR (acetone-d6): 7.67 (d, 2H), 7.62 (d, 2H), 7.60-7.51 (m, 3H), 7.39 (m, IH), 7.09 (t, IH), 7.00 (t, IH), 6.89 (s, IH), 4.47 (s, 2H), 4.09 (s, IH), 2.31 (s, 6H), 1.52 (s, 6H).
Example 61
'Proton NMR (acetone-d6): 7.90 (d, 2H), 7.80 (d, 2H), 7.61 (s, IH), 7.52 (s, IH), 7.20 (dd, IH), 7.00 (d, IH), 6.89 (s, IH), 4.50 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.35 (s, 6H). Example 62
'Proton NMR (acetone-d6): 7.66 (d, 2H), 7.53 (d, 2H), 7.49 (s, IH), 7.24 (d, IH), 7.19 (dd, IH), 6.99 (d, IH), 6.90 (s, IH), 4.46 (s, 2H), 4.04 (s, 2H), 3.88 (s, 3H), 2.34 (s, 6H).
Example 63
'Proton NMR (acetone-d6): 7.58 (d, 2H), 7.48 (s, IH), 7.45 (d, 2H), 7.21 (d, IH), 7.18 (dd, IH), 6.98 (d, IH), 6.89 (s, IH), 4.46 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 3.70 (s, 2H), 2.34 (s, 6H).
Example 64
'Proton NMR (acetone-d6): 8.16 (d, 2H), 7.77 (d, 2H), 7.55-7.53 (m, 2H), 7.50 (s, IH), 7.43-7.41 (m, 3H), 6.90 (s, IH), 4.50 (s, 2H), 2.32 (s, 6H).
Example 65
'CIMS: MH+: 517.2
Example 66
'Proton NMR (acetone-d6): 8.05 (d, 2H), 7.88 (d, 2H), 7.54 (s, IH), 7.25 (d, IH), 7.20 (dd, IH), 7.00 (d, IH), 6.89 (s, IH), 4.51 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 3.17 (s, 3H), 2.32 (s, 6H).
Example 67
Proton NMR (acetone-d6): 8.55 (d, 2H), 7.71 (d, IH), 7.59 (d, 2H), 7.41 (d, IH), 7.28 (s, IH), 7.26 (d, IH), 7.00 (d, IH), 4.92 ( , IH), 3.85 (s, 3H), 1.95- 1.60 (m, 8H).
Example 68
'Proton NMR (acetone-d6): 8.04 (d, 2H), 7.71 (d, 2H), 7.49 (s, IH), 7.22- 7.18 (m, 2H), 6.99 (d, IH), 6.90 (s, IH), 4.92 (m, IH), 4.49 (s, 2H), 3.83 (s, 3H), 2.33 (s, 6H), 2.00-1.60 (m, 8H).
Example 69
'Proton NMR (CDC13): 7.58 (d, 2H), 7.40 (d, 2H), 7.33 (s, IH), 7.14 (dd, IH), 7.08 (d, IH), 6.85 (d, IH), 6.67 (s, IH), 4.73 (s, 2H), 4 .42 (s, 2H), 3.90 (s, 3H), 3.87 (s, 3H).
Example 70
'Proton NMR (acetone-d6): 8.11 (d, 2H), 8.05 (d, 2H), 7.70 (m, IH), 7.57- 7.42 (m, 7H), 7.27 (t, IH), 6.83 (s, IH), 4.44 (s, 2H), 2.28 (s, 6H).
Example 71
'Proton NMR (acetone-d6): 11.18 (s, IH), 8.11 (d, IH), 7.78 (dd, IH), 7.47 (s, IH), 7.23 (d, IH), 7.17 (dd, IH), 7.08 (d, IH), 6.96 (d, IH), 6.87 (s, IH), 4.42 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.33 (s, 6H).
Example 72
•Proton NMR (acetone-d6): 8.51 (m, IH), 7.83-7.76 (m, 3H), 7.25-7.16 (m, 3H), 7.07 (d, IH), 6.91 (s, IH), 4.48 (s, 2H), 3.86 (s, 3H), 3.83 (s, 3H), 2.36 (s, 6H).
Example 73
'Anal.: C 63.07, H 4.92, N 5.69, S 12.60; (calc: C 63.4, H 4.92, N 5.69, S 12.99).
Example 74
'M.P.: 135.3°C
Example 75
'Proton NMR (CDC13): 7.88 (d, 2H), 7.69 (d, 2H), 7.50 (d, 2H), 7.36 (s, IH), 6.90 (d, 2H), 6.70 (s, IH), 4.46 (s, 2H), 3.85 (s, 3H), 2.36 (s, 6H).
Example 76
Proton NMR (CDC13): 9.12 (s, IH), 7.39 (dd, IH), 7.32 (d, IH), 7.31 (s, IH), 7.13 (dd, IH), 7.07 (d, IH), 6.92 (d, IH), 6.85 (s, IH), 6.71 (s, IH), 4.40 (s, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 2.55 (s, IH), 2.40 (s, 6H), 1.69 (s, 6H).
Example 77
'Proton NMR (acetone d-6): 8.90 (dd, IH), 8.52 (dd, IH), 8.05-8.01 (m, 3H), 7.83 (d, 2H), 7.74 (s, IH), 7.43 (ddd, IH), 6.90 (s, IH), 6.67 (bs, 2H, NH2), 4.53 (s, 2H), 2.32 (s, 6H).
Example 78
'M.P.: 146.1°C.
Example 79
'Proton NMR (acetone-d6): 12.33 (s, IH), 8.08 (d, IH), 7.71 (dd, IH), 7.44 (s, IH), 7.20 (d, IH), 7.13 (dd, IH), 7.02 (d, IH), 6.93 (d, IH), 6.86 (s, IH), 4.42 (s, 2H), 3.87 (s, 3H), 3.81 (s, 3H), 2.63 (s, 3H), 2.32 (s, 6H).
Example 80
'Proton NMR (acetone-d6): 7.45 (s, IH), 7.19 (d, IH), 7.15 (dd, IH), 6.97 (d, IH), 6.89 (s, IH), 6.575 (d, IH), 6.36 (d, IH), 4.60 (s, 2H), 4.32 (s, IH, OH), 3.88 (s, 3H), 3.82 (s, 3H), 2.37 (s, 6H), 1.57 (s, 6H).
Example 81
Proton NMR (acetone-d6): 7.51 (t, IH), 7.48 (s, IH), 7.45 (dt, IH), 7.37 (t, IH) 7.29 (dt, IH), 7.22 (d, IH), 7.17 (dd, IH), 6.97 (d, IH), 6.89 (s, IH), 4.45 (s, 2H), 3.88 (s, 3H), 3.82 (s, 3H), 3.40 (s, IH, OH), 2.80 (s, 2H), 2.34 (s, 6H), 1.16 (s,.6H).
Example 82
'Proton NMR (CDC13): 8.11 (d, 2H), 7.56 (d, 2H), 7.18-7.06 (m, 4H), 6.91- 6.82 (m, 3H), 6.75 (m, IH), 4.83 (m, IH), 4.14 (s, 2H), 3.86 (s, 3H), 3.72 (s, 3H), 2.00-1.60 (m, 8H).
Example 83
'Proton NMR (acetone-d6): 8.07 (d, 2H), 7.55 (dd, IH), 7.52 (d, 2H), 7.25 (s, IH), 7.20 (m, 2H), 7.08 (dd, IH), 7.03-6.99 (m, 2H), 4.12 (s, 2H), 3.85 (s, 3H), 2.00-1.60 (m, 8H).
Example 84
•Proton NMR (DMSO-d6): 8.43 (d, IH), 8.01 (d, 2H), 7.67 (d, 2H), 7.58 (d, 2H), 7.49 (s, IH), 7.09 (d, IH), 6.99 (d, 2H), 4.46 (s, 2H), 3.78 (s, 3H), 2.30 (s, 3H).
Example 85
Proton NMR (acetone-d6): 8.76 (d, IH), 8.68 (d. IH), 8.09 (t, IH), 7.52 (s, IH) 7.24 (d, IH), 7.20 (dd, IH), 7.00 (d, IH), 6.88 (s, IH) 4.46 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.32 (s, 6H), 1.58 (s, 6H).
Example 86
'Proton NMR (acetone d-6): 8.10 (d, 2H), 7.67 (d, 2H), 7.43-7.30 (m, 3H), 7.21 (d, IH), 7.20 (dd, IH), 7.13 (d, IH), 7.12 (dm, IH), 7.00 (d, IH), 4.27 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H).
Example 87
•Proton NMR (acetone d-6): 9.22 (bs, IH, OH), 8.01 (dd, IH), 7.62 (d, 2H), 7.53 (d, 2h), 7.44 (s, IH), 7.23 (d, IH), 7.17 (dd, IH), 7.12 (dd, IH), 7.00- 6.96 (m, 2H), 4.47 (s, 2H), 4.13 (s, IH, OH), 3.88 (s, 3H), 3.83 (s, 3H), 1.56 (s, 6H).
Example 88
"Proton NMR (CDC13): 8.62 (m, 2H), 7.50 (m, 2H), 7.34 (s, IH), 7.14 (dd, IH), 7.07 (d, IH), 6.86 (d, IH), 6.69 (s, IH), 4.50 (s, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 2.35 (s, 6H).
Example 89
•Proton NMR (acetone-d6): 7.70 (dd, IH), 7.46 (s, IH), 7.45-7.30 (m,
3H) 7.23 (d, IH), 7.17 (dd, IH), 6.97 (d, IH), 6.85 (s, IH) 6.66 (d, 2H), 6.45
(d, IH), 4.18 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.31 (s, 6H), 1.31 (s, 6H). Example 90
Proton NMR (acetone-d6): 7.71 (dd, IH), 7.62 (m, IH), 7.50 (s, IH), 7.25- 7.17 (m, 3H), 6.98 (d, IH), 6.87 (s, IH), 4.35 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.31 (s, 6H), 1.54 (s, 6H).
Example 91
'Proton NMR (acetone-d6): 8.28 (m, IH), 8.16 (d, 2H), 8.00 (m, 2H), 7.85 (d, 2H), 7.64 (m, IH), 7.57-7.53 (m, 3H), 7.51 (s, IH), 6.90 (s, IH), 4.60 (s, 2H), 3.42 (s, 3H), 2.32 (s, 6H).
Example 92
Cl
'Proton NMR (acetone-d6): 8.83 (d, 2H), 8.29 (s, IH), 8.27 (d, 2H), 7.25- 7.20 (m, 2H), 7.11 (d, IH), 6.93 (s, IH), 4.55 (s, 2H), 3.88 (s, 3H), 3.84 (s, 3H), 2.35 (s, 6H).
Example 93
'Proton NMR (CDC13): 7.60 (dd, 2H), 7.44 (t, 2H), 7.44-7.40 (m, 2H), 7.14 (dd, IH), 7.08 (d, IH), 6.86 (d, IH), 6.68 (s, IH), 4.46 (s, 2H), 3.93 (s, 3H), 3.90 (s, 3H), 2.37 (s, 6H).
Example 94
'Proton NMR (acetone d-6): 8.09 (d, 2H), 7.64 (d, 2H), 7.33 (s, IH), 7.21- 7.18 (m, 2H), 7.11 (bs, IH), 7.06 (d, IH), 7.00 (d, IH), 6.95 (bd, IH), 4.19 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H).
Example 95
Proton NMR (acetone d-6): 8.07 (d, 2H), 7.87-7.73 (m, 4H), 7.65 (d, 2H), 7.51-7.42 (m, 3H), 7.41 (s, IH), 7.18-7.16 (m, 2H), 6.98 (d, IH), 4.40 (s, 2H), 3.84 (s, 3H), 3.83 (s, 3H).
Example 96
•Proton NMR (CDC13): 8.11 (d, 2H), 7.59 (d, 2H), 7.26-7.20 (m, 2H), 7.17 (s, IH), 7.10 (dd, IH), 7.07 (d, IH), 6.88-6.79 (m, 3H),4.83 (m, IH), 4.12 (s, 2H), 3.86 (s, 3H), 3.80 (s, 3H), 2.00-1.60 (m, 8H).
Example 97
'Proton NMR (acetone d-6): 8.09 (d, 2H), 7.65 (d, 2H), 7.39 (s, IH), 7.23- 7.17 (m, 3H), 7.00 (d, IH), 6.91 (dm, IH), 6.88 (t, IH), 6.79 (ddd, IH), 4.28 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.73 (s, 3H).
Example 98
Proton NMR (acetone-d6): 8.52 (d, IH), 7.83 (m, 2H), 7.71 (d, IH), 7.38 (d, IH), 7.25 (m, 3H), 7.00 (d, IH), 4.95 (m, IH), 3.82 (s, 3H), 1.95-1.60 (m, 8H). Example 99
•Proton NMR (acetone-d6): 8.81 (m, IH), 8.59 (dd, IH), 7.99 (dm, IH), 7.52 (s, IH), 7.50 (m, IH), 7.25 (d, IH), 7.20 (dd, IH), 7.00 (d, IH), 6.89 (s, IH), 4.47 (s, 2H), 3.88 (s, 3H), 3.85 (s, 3H), 2.33 (s, 6H).
Example 100
'Proton NMR (acetone d-6): 810 (d, 2H), 7.64 (d, 2H), 7.38 (s, IH), 7.34- 7.28 (m, 4H), 7.23-7.19 (m, 2H), 7.00 (d, IH), 4.29 (s, 2H), 3.90 (s, 3H), 3.85 (s, 3H).
Example 101
•Anal.: C 54.04, H 3.16, N 4.71.
Example 102
Proton NMR (acetone-d6): 8.10 (d, 2H), 7.64 (d, 2H), 7.37 (s, IH), 7.23-7.18 (m, 2H), 7.00 (d, IH), 6.92 (s, 2H), 6.85 (s, IH), 4.23 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H), 2.18 (s, 6H).
Example 103
'Proton NMR (acetone-d6): 8.08 (d, 2H), 7.60 (d, 2H), 7.35 (s, IH), 7.22 (d, IH), 7.20 (dd, IH), 7.09 (bs, IH), 7.06-6.99 (m, 3H), 4.19 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 2.20 (s, 3H), 2.15 (s, 3H).
Example 104
'Proton NMR (acetone-d6): 8.11 (d, 2H), 7.70 (d, 2H), 7.36 (s, IH), 7.29- 7.18 (m, 4H), 7.00 (d, IH), 6.95 (dd, IH), 6.87 (td, IH), 4.20 (s, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 3.80 (s, 3H).
Example 105
Example 106
•M.P.: 113.9°C
Example 107
Proton NMR (acetone-d6): 7.56 (dd, 2H), 7.51 (s, IH), 7.25 (d, IH), 7.19 (dd, IH), 7.05 (dd, 2H), 6.98 (d, IH), 6.83(s, IH), 5.32 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H), 2.35 (s, 6H).
Example 108
Proton NMR (acetone-d6): 8.57 (d, 2H), 8.14 (d, 2H), 7.75 (d, 2H), 7.52 (s, IH), 7.26 (d, IH), 7.21 (dd, IH), 7.17 (t, IH), 7.00 (d, IH), 4.52 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H).
Example 109
'Proton NMR (acetone-d6): 7.64 (dd, 2H), 7.58 (dd, 2H), 7.55 (s, IH), 7.27 (d, IH), 7.20 (dd, IH), 6.99 (d, IH), 6.83 (s, IH), 5.36 (s, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 2.35 (s, 6H), 1.55 (s, 6H).
Example 110
'Proton NMR (acetone-d6): 8.87 (d, IH), 8.48 (dd, IH), 7.99 (dt, IH), 7.64 (d, 2H), 7.49 (d, 2H), 7.42 (s, IH), 7.40 (m, IH), 6.85 (d, IH), 6.75-6.70 (m, 2H), 4.70 (m, IH), 4.15 (s, IH, OH), 4.01 (s, 2H), 3.74 (s, 3H), 1.70-1.50 (m, 14H).
Example 111
'M.P.: 171.9°C (decomposed) Example 112
Proton NMR (acetone d-6): 8.63 (dm, IH), 7.86 (td, IH), 7.78 (dm, IH), 7.53 (s, IH), 7.30-7.20 (m, 3H), 6.99 (d, IH), 6.88 (s, IH), 4.81 (s, 2H), 3.90 (s, 3H), 3.83 (s, 3H), 2.36 (s, 6H).
Example 113
'Proton NMR (acetone-d6): 7.63 (d, 2H), 7.50 (d, 2H), 7.26 (s, IH), 6.88 (s, IH), 4.48 (s, IH), 4.41 (s, 2H), 4.06 (s, IH), 2.31 (s, 6H), 1.52 (s, 6H), 1.50 (s, 6H).
Example 114
"Proton NMR (acetone d-6): 8.45 (m, IH), 8.12 (d, 2H), 7.73 (d, 2H), 7.71
(m, IH), 7.59 (d, 2H), 7.44 (s, IH), 7.30 (d, IH), 7.14 (m, IH), 6.98
(d,2H), 4.56 (s, 2H), 3.83 (s, 3H).
Example 115
Proton NMR (acetone-d6): 8.09 (d, 2H), 7.61 (d, 2H), 7.41-7.38 (m, 2H), 7.33 (s, IH), 7.22-7.19 (m, 2H), 7.08-7.04 (m, 2H), 7.01 (d, IH), 4.23 (s, 2H), 3.89 (s, 3H), 3.85 (s, 3H).
Example 116
Proton NMR (acetone-d6): 8.10 (d, 2H), 7.66 (d, 2H), 7.36-7.34 (m, 2H), 7.31-7.18 (m, 5H), 7.00 (d, IH), 4.27 (s, 2H), 3.89 (s, 3H), 3.84 (s, 3H).
Example 117
•Proton NMR (acetone-d6): 8.57 (m, 2H), 7.76 (s, IH), 7.59 (m, 2H), 7.26 (d, IH), 7.15 (dd, IH), 7.04 (d, IH), 4.64 (d, 2H), 4.38 (t, IH, OH), 3.87 (s, 3H), 3.86 (s, 3H).
Methods of Synthesis
The compounds of the present invention can be prepared by the methods described below. It will be apparent to one skilled in the art that similar methodology could be used to prepare the enantiomers or the racemates of the illustrated compounds.
Method 1:
A variety of organic acids (bromobenzoic acids, bromophenylacetic acids, bromophenylpropionic acids, bromocinnamic acids, bromonicotinic acids, bromothiophenecarboxylic acids and bromofuroic acid, etc.) was loaded onto a Merrifield resin or a Wang resin according to known prior art [see: a) Gisin B.F. (1973) Helv. Chim. Ada 56, 1476; b) Wang S.-W. (1973) J. Am. Chem. Soc. 95, 1382; c) Lu G. et al (1981) J. Org. Chem. 46, 3433]. The palladium catalyzed cross- coupling reactions of these resin bound arylbromides with boronic acid 1 (the Suzuki reaction) were carried out according to the standard procedure described in the experimental to yield intermediates II (for a review of the Suzuki coupling reactions, see: Miyaura N. and Suzuki A. (1995) Chem. Rev. 95, 2457-2483; for an example of the Suzuki reaction on solid support, see: Frenette R. and Friesen R. (1994) Tetrahedron Lett. 35, 9177). Bromination of II with NBS (for an example of bromination of thiophene with NBS, see: Kellogg R. K. et al (1968) J. Org. Chem. 33, 1902) in THF in the presence of water afforded the corresponding bromothiophene which was then subjected to another Suzuki reaction with arylboronic acids to furnish resins HI. Reacting DI with Br2PPh3 gave the corresponding bromo resin IV (see:
(1964) J. Am. Chem. Soc. 86, 964); IV were then treated with nucleophiles (thiols, amines, phenols, and boronic acids, etc.) to give resins V which were cleaved with TFA to furnish the correspong carboxylic acids la (Wang resin) or with MeMgBr to yield the corresponding dimethylcarbinols lb.
Method 1: General Method for Solid Phase Synthesis
RaB(OH)2, Na2CO3 Pd(Ph3)4, DME
Method 2:
The procedures for solution synthesis were similar to that described for the solid phase synthesis except that every intermediate was purified and characterized. Additionally, the Heck coupling reactions (from intermediates VI to VH) were performed according to known literature procedures (for a review of the Heck reaction, see: de Meijere A. and Meyer F.E. (1994) Angew. Chem. Int. Ed. Engl. 33, 2379). Intermediates VII were reacted either with Br2PPh3 to give the corresponding bromides, or with MsCl and diisopropylethylamine in THF to afford the corresponding mesylates which were then reacted with nucleophiles to furnish products Ic. alternatively, VII were reacted with compounds bearing an acidic OH group under the Mitsimobo reaction conditions (for a review, see: Hughes D.L. (1996) OrganicPreparations and Procedures Int. 28, 127-164) to yield products ID.
Method 2: General Method for Solution Synthesis:
RbOH
Both Ara and Ra can be further (Mitsunobo reaction) modified to give derivatives
.0 yfc
(Id) The invention will now be illustrated by the following non- limiting examples in which, unless stated otherwise, all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5- 30 mm. Hg) with a bath temperature of up to 60°C; the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent; conventional abbreviations used for signal shape are: s. singlet; d. doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).
The example numbers below correspond to the example numbers (1-117) described above. Any examples listed above that are not mentioned or described below can be made by the combination of literature described methods and/or methods disclosed herein.
The following abbreviations have the indicated meanings: Ac = acetyl
Bn = benzyl
BSA bovine serum albumin cAMP cyclic adenosine-3',5'-monophosphate DBU l,8-diazabicyclo[5.4.0]undec-7-ene
DIBAL diisobutyl aluminum hydride DMAP 4-(dimethylamino)pyridine DMF N,N-dimethylformamide
Et3N triethylamine
GST glutathione transferase
LDA lithium diisopropylamide m-CPBA metachloroperbenzoic acid
MMPP monoperoxyphtalic acid
MPPM monoperoxyphthalic acid, magnesium salt 6H2O
Ms methanesulfonyl = mesyl = Sθ2Me
MsO methanesulfonate = mesylate
NSAID non-steroidal anti-inflammatory drug o-Tol ortho-tolyl
OXONE® 2KHSθ5»KHSθ4*K2Sθ4
PBS phosphate buffer saline
PCC pyridinium chlorochromate
PDC pyridinium dichromate
PDE phosphodiesterase
Ph phenyl
Phe benzenediyl
PMB para-methoxybenzyl
Pye pyridinediyl r.t. room temperature rac. = racemic
SAM aminosulfonyl or sulfonamide or SO2NH2
SPA scintillation proximity assay
TBAF = tetra-n-butylammonium fluoride
Th 2- or 3-thienyl
TFA trifluoroacetic acid
TFAA = trifluoroacetic acid anhydride
THF tetrahydrofuran
Thi thiophenediyl
TLC thin layer chromatography TMS-CN = trimethylsilyl cyanide
TNF tumor necrosis factor
Tz = IH (or 2H)-tetrazol-5-yl
Alkyl Group Abbreviations
Me = methyl
Et = ethyl n-Pr = normal propyl i-Pr = isopropyl n-Bu = normal butyl i-Bu = isobutyl s-Bu = secondary butyl t-Bu = tertiary butyl c-Pr = cyclopropyl c-Bu = cyclobutyl c-Pen = cyclopentyl c-Hex = cyclohexyl
Dose Abbreviations bid = bis in die = twice daily qid = quater in die = four times a day tid = ter in die = three times a day
The following schemes illustrate intermediates to which reference is made in the description of the Examples.
Scheme 1: Resin Intermediates
Resin A Resin B Resin C
= Wang Resin
Resin D Resin E
Resin F Resin G
Scheme 2: Chemical Intermediates
10 11
15 16 17
21 Experimental
Example 2: 3-(4,6-Dimethylpyrimidin-2-yl)thiomethyl-2-[4-(l-hydroxy-l- methylethyDphenyl] -5- [2-(4-methylpiperazin- l-yl)pyridin-5-yl] thiophene
A mixture of bromide 16 (257mg), lithium 2-(4-N- methylpiperazino)pyridine-5-trimethylboronate salt (657mg), Pd(PPh3)4 (20mg) in DME/H20 was heated to 80C overnight and worked up as usual. The crude product was purified by flash chromatography. Eluting with 5% MeOH in CH2C12 afforded the title compound (80mg) as a white solid. Η NMR: see Table 1.
Examples 9, 17, 20 and 24 were prepared similarly.
Example 3: 3-(4.6-Dimethylpyrimidin-2-yl)thiomethyl-2-f4-(l-hydroxy-l- methylethyPphenyl 1 -5- f 3-(4-pyridyloxy)phenyll thiophene
A mixture of Example 26 (48mg), 4-chloropyridine (31mg) and K2CO3 (45mg) in DMAC was heated to reflux for 3h and cooled to rt. The mixture was diluted with water and extracted with ethyl acetate. The extract was washed with brine dried over MgS04, filtered and concentrated. The residue was purified by flash chromatography. Eluting with 4:1 ethyl acetate in hexanes afforded the title compound (36mg, 64% yield) as a white solid. Η NMR: see Table 1.
Examples 4 and 10 were prepared similarly.
Example 8: 2-(4-Carboxyphenyl)-5-(-3.4-dimethoxyphenyl)-3-(4.6- dimethylpyrimidin-2-yl)thiomethylthiophene
Step 1. Preparation of Intermediate 2: To a solution of ethyl 4- bromobenzoate (2.29g, lOmmol) in DME (40mL) was added boronic acid 1 (2.37g, lδmmol), Pd(PPh3)4 (346mg, 0.3mmol) and Na2C03 (2M, 7.5mL) and the mixture was deoxygenated under a stream of N2 for 5 min and then heated to 80° C for 50 min. After cooling to rt, the mixture was diluted with H20 and extracted with ethyl acetate (3 x 50mL). The extracts were combined, washed with water, brine, dried over Mg2S04 and then filtered through a sintered funnel. The filtrate was concentrated in vacuo and the residue purified by flash chromatography (eluting with 40% ethyl acetate in hexanes) to afford intermediate 2 (2.7g, 100%) a yellow powder. Η NMR (400 MHz, CDC13): δ8.07 (d, 2H), 7.56 (d, 2H), 7.33 (d, IH), 7.20 (d, IH), 4.69 (d, 2H), 4.28 (q, 2H), 1.62 (t, IH, OH), 1.40 (t, 3H). This procedure will be referred to as the standard Suzuki coupling reaction conditions in solution.
Step 2. Bromination to Intermediate 3: To a solution of intermediate 2 (2.7g, lOmmol) in THF (50mL) at 0°C was added NBS (3.56g, 20mmol) and water (5mL) and the mixture was stirred at 0°C for 30 min and quenched with excess 5% Na2S203 aqueous solution. The mixture was then extracted with ethyl acetate (3 x 50mL) and the extracts combined, washed with water, brine, dried over Mg2S04 and filtered. The filtrate was concentrated in vacuo and the residue was purified by flash chromatography (eluting with 40% ethyl acetate in hexanes) to afford 3.24g (95% yield) of bromide 3 as a white crystalline solid after recrystaUization from ether and hexanes. Η NMR (400 MHz, CDC13): δ 8.06 (d, 2H), 7.48 (d, 2H), 7.16 (s, IH), 4.61 ( d, 2H), 4.38 (q, 2H), 1.75 (t, IH), OH), 1.39 (t, 3H).
Step 3. Preparation of Intermediate 4: To a solution of bromide 3 (610mg, 1.79mmol) in DME (8mL) was added 3,4-dimethoxyphenylboronic acid (391mg, 2.15mmol) (see: Yokoe, I. et al, (1989) Chem. Pharm. Bull. 37, 529), Pd(PPh3)4 (62mg, 0.054mmol) and Na2C03 (lmL, 2M) and the mixture was deoxygenated under a stream of nitrogen for 5 min, heated to reflux for 4h, and then cooled to rt and diluted with water. The mixture was then extracted with ethyl acetate (3x) and the extracts combined, washed with water, brine, dried over MgS04, filtered and concentrated to give the crude product which was purified by flash chromatography (50% ethyl acetate in hexanes) to yield compound 4 (0.65mg, 91% yield) as a yellow solid after recrystaUization from ethyl acetate and hexanes. Η NMR (400MHz, Acetone-d6): δ8.08 (d, 2H), 7.73 (d, 2H), 7.48 (s, IH), 7.25 (d, IH), 7.21 (dd, 2H), 7.00 (d, IH), 4.65 (d, 2H), 4.38 (t, IH, OH), 4.37 (q, 2H), 3.90 (s, 3H), 3.85 (s, 3H), 1.38 (t, 3H).
Step 4. Preparation of Intermediate 5: To a solution of compound 4 (461mg, l.lβmmol) in CH2C12 (6mL) at 0°C was added Br2PPh3 (586mg, 1.39mmol) and the solution was allowed to warm to rt and stirred for 30 min under N2. Then to the solution was added 4,6-dimethyl-2- mercaptopyrimidine (325mg, 2.32mmol) and diisopropylethylamine (0.8mL) and the resultant solution was stirred at rt for lh and concentrated. The residue was purified by flash chromatography (40- 50% ethyl acetate in hexanes) to afford compound 5 (663mg, 91% yield) as a light yellow solid. Η NMR (400 MHz, acetone-d6): 58.11 (d, 2H), 7.76 (d, 2H), 7.53 (s, IH), 7.25 (d, IH), 7.20 (dd, IH), 6.99 (d, IH), 6.90 (s, IH), 4.50 (s, 2H), 4.37 (q, 2H), 3.90 (s, 3H), 3.84 (s, 3H), 2.33 (s, 6H), 1.38 (t, 3H).
Step 5. Hydrolysis: A mixture of compound 5 (213mg, 0.41 mmol) and LiOH (1.23mL, IM) in dioxane (5mL) was heated to 80°C for 2h and cooled to rt, diluted with water and acetic acid and then extracted with ethyl acetate. The extract was washed with water, brine, dried over MgSO4, filtered and concentrated. The crude was crystallized from ethyl acetate and hexanes to give the title compound as a white powdery solid (189mg, 94% yield). MP 238.8°C .
Alternative method:
Step 1. Preparation of Intermediate 6: To a solution of bromide 3 (lllmg, 0.36mmol) dissolved in CH2C12 (2 mL) was added Br2PPh3 (227mg, 0.54mmol) at 0°C and the mixture was stirred at 0°C under N2 for lh. To the solution was added a solution of 4,6-dimethyl-2-mercaptopyrimidine in DMF (IM, 0.54mL) and diisopropylethylamine (93uL) and the mixture stirred at rt for 30 min, diluted with water and extracted with ethyl acetate. The extract was washed with brine, dried over MgS04, filtered and concentrated. The residue was purified by flash chromatograph (30% ethyl acetate in hexanes) to give compound 6. XH NMR (400 MHz, acetone-d6): δ 8.11 (d, 2H), 7.70 (d, 2H), 7.33 (s, IH), 6.89 (s, IH), 4.45 (s, 2H), 4.39 (q, 2H), 2.31 (s, 6H), 1.36 (t, 3H).
Step 2. Preparation of Intermediate 5: Bromide 6 from above was reacted with 3,4-dimethoxyphenylboronic acid in a similar manner to that used to prepare compound 4, to yield compound 5.
Examples 27, 32, 34, 39, 42, 44, 49, 52, 54, 58, 59, 63, 73, 84, and 101 were prepared using technology similar to that described above.
Example 13: 5-(3.4-Dimethoxyphenyl)-3-(4.6-dimethylpyrimidin-2- yl)thiomethyl-2-[4-(l-hydroxy-l-methylethyl)phenyl1thiophene
To a solution of compound 5 (1.3g) in THF (lOmL) was added MeMgBr (10.3 mL, 1.4M in THF/Toluene) at 0°C and the solution was stirred at rt for 30 min and quenched with NH4C1 (sat'd aq) and extracted with ethyl acetate (2x50mL). The extracts were combined, washed with brine, dried over MgS04 and filtered. Concentration of the filtrate gave a yellow residue which was purified by flash chromatography, eluting with 60% ethyl acetate in hexanes. The title compound was crystallized from
CH2C12 and hexanes as a light yellow flaky solid (1.2g, 95% yield). M.P.: 71.5°C; Η NMR (400MHz, acetone-d6): δ7.64 (d, 2H), 7.55 (d, 2H), .47 (s, IH), 7.22 (d, IH), 7.18 (dd, IH), 6.97 (d, IH), 6.88 (s, IH), 4.46 (s, 2H), 4.09 (s, IH, OH), 3.88 (s, 3H), 3.83 (s, 3H), 2.33 (s, 6H), 1.55 (s, 6H).
Examples 38, 74, and 76 were prepared in a similar manner.
Example 18: 5-(3.4-Dimethoxyphenyl)-3-(4.6-dimethylpyrimidin-2- yl)thiomethyl-2-.r4-(l-hydroxycyclobutyl)phenyll thiophene
Step 1. One pot preparation of 4-trimethylsilylphenylboronic acid (see: Kaufmann et al, (1987) Chem. Ber. 120, 901): To a solution of p- dibromobenzene (11.8g, 50mmol) in THF (250mL) at -78°C was added n- BuLi (20mL, 2.5M in hexanes) over 2 min and the mixture was stirred at -78°C for 2 min. TMSC1 (6.3mL, 50mmol) was added in one portion and the resultant mixture was stirred at -78° C for 10 min. n-BuLi (20mL) was added again over 2 min and stirring was continued for 10 min at - 78°C followed by the addition of triisopropylborate (13mL, 55mmol) quickly and the mixture was stirred at -78° C for 30 min, allowed to warm to rt, quenched with water, AcOH (2.5 eq) and then extracted with ethyl acetate (3xl00mL). The extracts were combined, washed with water and concentrated to afford 9g of the title boronic acid as a white solid which was further recrystallized from hexanes to give a grey white powder. Η NMR (400MHz, acetone-d6): δ7.85 (d, 2H), 7.53 (d, 2H), 7.11 [s, 2H, B(OH)2], 0.25 (s, 9H).
Step 2. Preparation of Intermediate 10. The boronic acid (4.96g, 25.5mmol) from Step 1 was reacted with 2-bromo-3- hydroxymethylthiophene (4.7g, 24.3mmol) (prepared from 3- thiophenemethanol with NBS in THF) under the standard Suzuki coupling conditions to yield intermediate 10 in 73% yield. αH NMR (400MHz, acetone-d6): δ7.62 (d, 2H), 7.54 (d, 2H), 7.39 (d, IH), 7.21 (d, IH), 4.62 (d, 2H), 4.17 (t, IH, OH), 0.29 (s, 9H).
Step 3. Preparation of Intermediate 11 Compound 10 (4.6g, 17.5mmol) in THF (80mL) was treated with NBS (6.25g) at rt for 2h and quenched with 10% Na2S203 and then extracted with ethyl acetate. The extract was washed with water, brine, dried over MgS04, filtered and concentrated. The residue was purified by flash chromatography (eluting with 20% ethyl acetate in hexanes) to furnish 5.42g (90% yield) of bromide 11. H NMR (400MHz, acetone-d6): δ7.62 (d, 2H), 7.49 (d, 2H), 7.23 (s, IH), 4.57 (d, 2H), 4.31 (t, IH, OH), 0.29 (s, 9H).
Step 4. Preparation of Intermediate 12: Bromide 11 (2g, 5.86mmol) was reacted with 3,4-dimethoxyphenylboronic acid (1.28g, 7mmol) under the standard Suzuki coupling reaction conditions to afford intermediate 12 (2.2g, 94% yield) as a white solid. Η NMR (400MHz, acetone-d6): 57.63 (d, 2H), 7.57 (d, 2H), 7.44 (s, IH), 7.25 (d, IH), 7.20 (dd, IH), 6.99 (d, IH), 4.63 (d, 2H), 4.23 (t, IH, OH), 3.90 (s, 3H), 3.84 (s, 3H), 0.30 (s, 9H).
Step 5. Preparation of Intermediate 13: Compound 12 (1.41g, 3.54mmol) was treated with a solution of IC1 (8.85mL, IM in CH2C12) at rt for lh and quenched with 10% Na2S203. The mixture was extracted with CH2C12 and the extract was concentrated. The residue was purified by flash chromatography (40% ethyl acetate, 10% CH2C12 in hexanes) to give iodide 13 (1.3g, 81% yield) as a light brown solid. Η NMR (400MHz, acetone-d6): δ7.83 (d, 2H), 7.43 (s, IH), 7.41 (d, 2H), 7.24 (d, IH), 7.20 (dd, lh), 6.99 (d, IH), 4.59 (d, 2H), 4.32 (t, IH, OH), 3.89 (s, 3H), 3.83 (s, 3H).
Step 6. Preparation of Intermediate 14: To a solution of iodide 13 (lg, 2.21mmol) in CH2C12 was added Br2PPh3 (1.12g, 2.65mmol) and the mixture stirred at rt for 30 min. 4,6-Dimethyl-2-mercaptopyrimidine (619mg, 4.42mmol) and diisopropylethylamine (1.54mL) were introduced and the mixture was stirred at rt for lh, concentrated and the residue purified by flash chromatography (40% ethyl acetate in hexanes) to give compound 14 (1.28g, 100% yield) as a light yellow solid. Η NMR (400MHz, acetone-d6): δ7.86 (d, 2H), 7.49 (s, IH), 7.42 (d, 2H), 7.23 (d, IH), 7.18 (dd, IH), 6.98 (d, IH), 6.90 (s, IH), 4.45 (s, 2H), 3.88 (s, 3H), 3.83 (s, 3H), 2.33 (s, 6H).
Step 7. To a solution of iodide 14 (68mg) and cyclobutanone (20μL) in ether (2mL) and THF (2mL) cooled to -100°C was added n-BuLi (O.llmL) and the mixture was allowed to warm to -70°C, quenched with water and extracted with ethyl acetate. The extract was washed with brine, dried over MgS04, filtered, concentrated and the crude was purified by flash chromatography (2:1 hexanes/ethyl acetate) to yield the title compound (52mg, 85% yield) as a white solid. Η NMR: see Table 1.
Examples 25, 33, and 61 were prepared similarly.
Example 21: 5-(3.4-Dimethoxyphenyl)-3-(4.6-dimethylpyrimidin-2- yl,thiomethyl-2-(4-methylthiophenyl)thiophene Step 1. Preparation of Intermediate 7: A mixture of thioanisolyl-4- boronic acid (2.2g, 13mmol) (see: Santucci et al, (1958) J. Am. Chem. Soc. 80, 193), 2-bromo-3-hydroxymethylthiophene THP ether (3g, 10.83nmol), Pd(PPh3)4 (374mg, 0.324nmol) and Na2C03 (6.5mL, 2M) in DME (33mL) was deoxygenated under a stream of N2 and heated to reflux overnight and worked up as usual. The crude product was purified by flash chromatography (10% ethyl acetate in hexanes) to afford 3.26g of coupling product 7. Η NMR (400MHz, acetone-d6) δ7.49 (d, 2H), 7.40 (d, IH), 7.35 (d, 2H), 7.17 (d, IH), 4.70 (t, IH), 4.69 (d, IH), 4.46 (d, IH), 3.81 (m, IH), 3.48 (m, IH), 2.53 (s, 3H), 1.90-1.40 (m, 6H).
Step 2. Preparation of Intermediate 8: The product from Step 1 was dissolved in 50mL of THF/1N HCl (4/1) and heated to reflux for 3h and cooled to rt. To the mixture was then added NBS (4.53g) and the resultant solution stirred at rt for 2h and quenched with 5% Na2S2O3 and then extracted with ethyl acetate (3 x 50mL). The extracts were combined, washed with water, brine, dried over MgS04, filtered and concentrated. The crude was purified by flash chromatography (5% ethanol in ethyl acetate) to yield 1.8g of sulfoxide 8. H NMR (acetone-d6, 400MHz): δ7.78 (d, 2H), 7.71 (d, 2H), 7.28 (s, IH), 4.59 (d, 2H), 4.43 (bt, IH, OH), 2.90 (s, 3H). Alternatively, the same compound was prepared from the reaction of boronic acid 1 and 4-bromothioanisole under the Suzuki coupling reaction conditions and the resultant product brominated in a similar manner as described.
Step 3. Preparation of Intermediate 9: To a solution of sulfoxide 8 (1.8g, 6mmol) in CH2C12 (40mL) was added Br2PPh3 (5.08g, 12mmol) at rt and the mixture stirred at rt for lh. To the mixture was then added 4,6- dimethyl-2-mercaptopyrimidine (2.52g, 18mmol) and diisopropylethylamine (5.2mL, 30mmol) and the mixture stirred at rt for lh and concentrated. The residue was purified by flash chromatography to yield compound 9 as a white solid (2.3g, 88% yield). Η NMR (400MHz, acetone-d6): δ7.48 (d, 2H), 7.37 (d, 2H), 7.27 (s, IH), 6.89 (s, IH), 4.40 (s, 2H), 2.54 (s, 3H0, 2.33 (s, 6H). Step 4. A mixture of 9 (700mg, 1.6mmol), 3,4-dimethoxyphenylboronic acid (350mg, 1.92mmol), Pd(PPh3)4 (55mg, 0.048mmol) and Na2C03 (lmL, 2M) in DME (5mL) was heated to reflux for 2h and worked up as usual. The crude product was purified by flash chromatography (40% ethyl acetate in hexanes) to yield the title compound (711mg, 90% yield) as a yellowish solid after crystallization from CH^l^exanes. H NMR: see Table 1.
Examples 4, 7, 15, 24, and 28 were prepared similarly by reacting intermediate 9 with the appropriate boronic acids and further modifications.
Example 26: 3-(4.6-Dimethylpyrimidin-2-yl)thiomethyl-2-f4-(l-hydroxy-l- methylethyl.phenyl1-5-(3-hydroxyphenyl)thiophene
Step 1. Preparation of Intermediate 15: To a solution of compound 2 (4g) in THF (80mL) was added MeMgBr (51mL, 3M in THF) in THF (80mL) at 0°C under N2 and the resulting mixture was stirred at that temperature for 1 h, quenched with IN HCl and extracted with ethyl acetate. The crude was purified by flash chromatography (2:1 hexanes/ethyl acetate) to give 3g (79%) of product 15. Η NMR (400MHz, acetone-d6): δ7.60 (d, 2H), 7.49 (d, 2H), 7.36 (d, IH), 7.20 (d, IH), 4.61 (d, 2H), 4.15 (t, IH, OH), 4.05 (s, IH, OH), 1.54 (s, 6H).
Step 2. Preparation of Intermediate 16: Compound 15 (3.0g) was dissolved in THF (lOOmL) and cooled to 0°C. To the solution was added NBS (4.3g) and H20 (lmL) and the mixture stirred at 0°C for lh, quenched with Na2S203 and NaHC03 and extracted with ethyl acetate. The crude product was purified by flash chromatography (2:1 hexanes/ethyl acetate) to yield bromide 16. lΕL NMR (400MHz, acetone- d6): δ7.62 (d, 2H), 7.44 (d, 2H), 7.20 (s, IH), 4.58 (d, 2H), 4.30 (t, IH, OH), 4.10 (s, IH, OH), 1.55 (s, 6H).
Step 3. Preparation of Intermediate 17: To a solution of bromide 16 (2.6g) in THF (lOmL) and CH2C12 (lOmL) at 0°C was added MsCl (0.54mL) and diisopropylethylamine (1.33mL) and the mixture was stirred at 0°C for 2h. 4,6-Dimethyl-2-mercaptopyrimidine (1.36g) was added followed by diisopropylethylamine (3.63mL) and the mixture was stirred for an additional 15 min at 0°C and then at rt for 20 min. Concentration in vacuo afforded the crude product which was purified by flash chromatography (2:1 hexanes/ethyl acetate). Compound 17 (2.8g, 82% yield) thus obtained exists as a white solid. XH NMR (300MHz, acetone- d6): δ7.64 (d, 2H), 7.48 (d, 2H), 7.26 (s, IH), 6.86 (s, IH), 4.41 (s, 2H), 4.10 (s, IH, OH), 2.31 (s, 6H), 1.54 (s, 6H).
Step 4. Example 26: A mixture of the bromide 17 (983mg), 3-allyloxy- phenylboronic acid (623mg, prepared by reacting 3-bromophenol allyl ether with n-BuLi and triisopropylborate), Pd(PPh3)4 (81mg) and Na2C03 (2.3mL, 2M) in DME was deoxygenated under nitrogen and then heated to reflux overnight. The mixture was cooled to rt and worked up as usual. To the crude product dissolved in THF (lOmL) was added Pd(PPh3)4 (85mg) and pyrrolidine and the mixture was degassed under nitrogen and heated to reflux for lh, cooled to rt, acidified with IN HCl and extracted with ethyl acetate. The crude product thus obtained was purified by flash chromatography (1:1 hexanes/ethyl acetate) to yield the title compound as a white solid. H NMR: see Table 1.
Example 35: 2-(4-Carboxyphenyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)- 3-(4.6-dimethylpyrimidin-2-yl)thiomethylthiophene
Step 1. Preparation of 3-hydroxymethylthiophene-2-boronic acid (1): To a solution of 2-(dihydroxyboranyl)thiophene-3-carboxaldehyde (prepared from thiophene-3-carboxaldehyde dimethyl acetal by a modified literature procedure, see: Gronowitz, S. et al, (1967) Ada Chem. Scand. 21, 2151) (3.34g, 0.214mol) in ethanol (20mL) at 0°C under nitrogen was added NaBH4 (0.81g, 0.21mol) in portions in 10 min. After stirring for 30 min at 0°C, the mixture was quenched with water and NH4C1 (sat'd aq.). The pH was adjusted with IN HCl -5-6 and the mixture was extracted with ethyl acetate (5 x 30mL). Evaporation of the extracts afforded the title compound as a white powdery solid (3.5g, 100%): XH NMR (400MHz, Acetone-d6 + 1 drop D20): δ7.52 (d, IH), 7.03 (d, IH), 4.78 (s, 2H). The product was kept under nitrogen at -20°C to avoid decomposition.
Step 2. Preparation of Resin B: Reaction of 1 with polymer bound (Wang resin) 4-bromobenzoate (resin A): To a suspension of the resin (6.16g, 5.3 mmol, 0.86mmol g loading) in DME (30mL) was added boronic acid 1 (1.67g, 10.6mmol), Pd(PPh3)4 (184mg, O.lβmmol) and Na2C03 (2M solution, 5.3mL) and the mixture was deoxygenated under a stream of nitrogen for 5 min under gentle stirring and then heated to 85° C under nitrogen overnight. The mixture was filtered when hot and the resin washed sequentially with DMF (3x), DMF/H20 (3x), DMF (2x), THF (2x) and then MeOH (3x) and dried under nitrogen flow for 48 h to yield resin B.
Step 3. Preparation of Resin C: Resin B was suspended in 60mL of THF and cooled to 0°C. NBS (1.9g, 10.6mmol) was added followed by lmL H2O and the mixture was allowed to warm to rt for 11/2 h and filtered. The resin was then washed with THF (3x), DMF (3x), THF (2x) and MeOH (3x) and dried under nitrogen and then under vacuum to give resin C.
Step 4. Preparation of 3-Cyclopentyloxy-4-methoxyphenylboronic acid: To a solution of 4-bromo-2-cyclopentyloxy-l-methoxybenzene (3.4g, 12.5mmol) (see: Meyer, A. I. et al, (1993) J. Org. Chem. 58, 36) in THF (60mL) at -78°C was added n-BuLi (5.2mL, 2.4M in hexanes) over 2 min and the resultant solution stirred at -78°C for 5 min. Triisopropylborate (3mL) was added in one portion and the mixture was stirred at -78°C for 20 min, allowed to warm to rt, and quenched with water and acetic acid (0.75mL). Concentration in vacuo afforded a white solid which was filtered. The white solid was washed twice with water and dried under reduced pressure to give the title compound (2.64g, 89% yield) as a white powder. Η NMR (400MHz, acetone-d6 + 1 drop D20): 57.44-7.41 (m, 2H), 6.90 (d, IH), 4.80 (m, IH), 3.77 (s, 3H), 1.90-1.50 (m, 8H). Step 5. Preparation of Resin D: General procedure for the Suzuki coupling reaction on solid support: A suspension of resin C (2.76g), 3- cyclopentyloxy-4-methoxy-phenylboronic acid (1.56g, 6.6mmol), Pd(PPh3)4 (77mg, 0.066mmol) and Na2C03 (2M, 3mL) in DME (27mL) was deoxygenated under a stream of nitrogen for 5 min and then heated to reflux for 7 h and poured into a 70 mL fritted polypropylene tube. The solvents were flushed out with a stream of nitrogen and the resin washed sequentially with DMF (3x) DMF/H2O (3x), DMF (2x), THF (2x) and MeOH (3x) and then dried under nitrogen overnight to afford 2.9g of resin D.
Step 6. Preparation of Resin E: Converting CH2OH to CH2Br: To a suspension of resin D (2.9g) in dichloromethane (30mL) under N2 at 0°C was added Br2PPh3 (1.5g, 3.48mmol) and the mixture was allowed to warm to rt with gentle stirring and then filtered. The residual resin was washed with CH2C12 (3x), THF (3x), ethyl acetate (2x) and ether (3x), and dried under reduced pressure to give resin E.
Step 7. Final product: To a suspension of resin E (50mg) in DMF (0.5mL) in a 5-mL fritted polypropylene tube equipped with a Teflon™ stopcock was added a solution of 4,6-dimethyl-2-mercaptopyrimidine in DMF( 200μL, IM) and diisopropylethylamine (50μL) and the mixture was shaken for 1 h at rt. The solvent was drained and the residue washed with DMF (3x), THF (3x), MeOH (3x ) and CH2C12 (3x) and the resultant resin was then treated with lmL 20%TFA in CH2C12 (containing 5% dimethyl sulfide) for 30 min. The liquid was drained to a round bottom
_ flask and the residual resin washed with CH2C12 (3x) and again drained to the flask. Evaporation of volatiles afforded the title compound as a yellow solid. Η NMR: see Table 1.
Examples 27, 82, 83, 86, 94, 95, 96, 97, 100, 102, 103, 104, 108, 114, 115, and 116 were prepared similarly.
Examples 14, 40, 43, 48, 50, 78, 80, 81, 85, 87, 89, and 90 were synthesized from the corresponding polymer (Merrifield or Wang resins) bound bromides according to similar procedures as described for Example 35 except for the cleavage. The Cleavage were carried out using MeMgBr (1.4M in THF/toluene, 20eq) in THF at room temperature for 2-12h and filtered through fritted polypropylene reservoirs. The filtrates were quenched with NH4C1 (saturated aq.) and extracted with ethyl acetate. The crude products were purified by preparative TLC.
Example 106: 5-(4-Carboxyphenyl)-2.3-bis((3-cyclopentyloxy-4- methoxy)phenyl)thiophene
Step 1. Preparation of boronic acid 18: To a solution of 3-trimethylsilyl- thiophene (1.56g) in THF (15mL) at -78°C was added a THF solution of LDA (pre-prepared from 1.68mL of diisopropylamine and 4.6mL 2.4M n- BuLi in THF) via a cannula and the resultant solution was stirred at - 78°C for 10 min, rt for 30 min and cooled to -78°C again.
Triisopropylborate (1.37mL) was added and stirring was continued for lh at -78° C and rt for 30 min. The mixture was then quenched with H20 and partitioned between hexanes and H20. The aqueous phase was acidified with acetic acid to pH~5 and extracted with ethyl acetate (3x). The extracts were concentrated and the crude was recrystallized from acetone/H20 to yield 18 (1.41g) as a white powder. Η NMR (400MHz, acetone-d6): 57.79 (m, 2H), 7.25 (bs, 2H), 0.25 (s, 9H).
Step 2. Preparation of Intermediate 19: A solution of ethyl 4- bromobenzoate (460mg), boronic acid 18 (500mg), Pd(OAc)2 (13.5mg),
PPh3 (32mg) in DMF (3mL) and Et3N (3mL) was heated to 90° C overnight and cooled to rt. The mixture was diluted with water and extracted with ether (3x). The extracts were combined, washed with water, brine, dried over MgS04 and concentrated. The residue was purified by flash chromatography (5% ethyl acetate in hexanes) to give compound 19
(584mg) as a yellow oil. Η NMR (400MHz, CDC13): 58.02 (d, 2H), 7.66 (d, 2H), 7.42 (d, IH), 7.41 (d, IH), 4.37 (q, 2H), 1.39 (t, 3H), 0.28 (s, 9H).
Step 3. Preparation of Intermediate 20: A solution of 19 (470mg), NBS (550mg) and AcOH (lmL) in THF was heated to reflux for 2h and cooled to rt. The mixture was treated with aqueous Na2S2O3 and extracted with ethyl acetate. The extract was concentrated and the crude purified by flash chromatography to give compound 20. Η NMR (CDC13, 400MHz): 58.05 (d, 2H), 7.53 (d, 2H), 7.18 (s, IH), 4.36 (q, 2H), 1.40 (t, 3H).
Step 4. A mixture of 20 (303mg), 3-cyclopentyloxy-4- methoxyphenylboronic acid (373mg), Pd(PPh3)4 (27mg) and Na2CO3(0.8mL, 2M) in DME (7mL) was deoxygenated under N2 and heated to reflux for 5h and worked up as usual. Purification of the crude by flash chromatography failed to give compound 21 in its pure form. As a result, the fraction containing 21 (180mg) was dissolved in dioxane (lmL) and H20 (lmL) containing LiOH monohydrate (46mg) and the mixture was heated to 70° C for 2h and cooled to rt. The mixture was acidified with IN HCl and then extracted with ethyl acetate. The crude product was purified by flash chromatography (60% ethyl acetate, 5% ethanol in hexanes) to afford the title compound. M.P.: see Table 1.
Example 110: 3-(3-Cvclopentyloxy-4-methoxy)benzyl-2-r4-(l-hydroxy-l- methylethyl)phenyl.-5-(3-pyridin-l-yl)thiophene
Step 1. Preparation of Resin F: A suspension of resin C (4.3g), lithium pyridine-3-trimethylboronate (1.81g) (see: Fischer et al, (1974) Reel Traυ.
Chim. Pays-Bas 93, 21) and Pd(PPh3)4 (199mg) in DME (32mL) and H20
(4mL) was deoxygenated under N2 for 5 min and then heated to reflux overnight. The mixture was filtered and the residue washed with DMF
(3x), DMF/H20 (3x), THF (2x), CH2C12 (2x) and MeOH (3x) and dried under reduced pressure to yield resin F.
Step 2. Preparation of Resin G: To a suspension of resin F (4.3g) in CH2C12 (30mL) was added Br2PPh3 (2.18g) and the suspension was stirred at rt for lh and filtered. The residue was washed with CH2C12 (3x), DMF (3x), THF(2x), ethyl acetate (2x) and ether (2x), and then dried under reduced pressure to afford resin G. Step 3. A mixture of resin G (96mg), 3-cyclopentyloxy-4-methoxy- phenylboronic acid (54mg), Pd(PPh3)4 (4.4mg) and CsF (70mg) was deoxygenated under N2 for 5 min and heated to 80° C for 2h. The mixture was filtered when hot and the residue washed with DMF (3x), DMF/H20 (3x), DMF, THF (2x) and MeOH (3x) and then dried under reduced pressure. To the dried resin suspended in THF (lmL) was added MeMgBr (lmL, 1.4M in THF/Toluene) and the mixture was stirred at rt for 2h. The mixture was filtered and the residue washed twice with THF/H20 (4:1). The filtrate and the washing solutions were combined, quenched with NH4C1 (aq) and extracted with ethyl acetate (3x). The extracts were concentrated and the residue purified by preparative TLC to yield the title compound. H NMR: see Table 1.
Assays for Determining Biological Activity
Establishment of CHO-K1 cell lines stably expressing PDE PVa enzyme
CHO-Kl cells stably expressing the prostacyclin receptor and grown under G418 selection as described previously (Y. Boie, et al. J. Biol. Chem.: 269, 12173-12178, 1994) were plated at a density of 1.75 x 106 cells/175cm2 in a T-175 flask (Gibco, Burlington, VT) containing alpha MEM media; 10% heat inactivated fetal bovine serum (FBS); 1% (v/v) penicillin/streptomycin; 25 mM Hepes, pH 7.4; and 500 μg/ml G418 (complete media). The cells were placed in an incubator for 24 hr at 37°C and 5% C0 . The cells were then washed with warmed sterile phosphate buffered saline (PBS) and incubated with 2μg/ml DNA, and 9 μg/ml lipofectamine reagent in Opti-MEM for 7 hr. At 37°C and 5% C02. The incubation solution was diluted 1:2 with Opti-MEM containing 20% FBS and incubated overnight. Following the overnight incubation, the media was replaced by complete media containing 500 μg/ml hygromycin B. Colonies were identified and grown in T-175 flasks for further characterization.
Measurement of whole-cell cAMP content
CCHHOO--KKll cceellllss wweerree ppllaatteedd aatt aa density of 10 cells/175 cm containing complete media with 500 μg/ml hygromycin. The flasks were maintained in an incubator at 37°C with 5.0% C02 for 72 hr. The media was changed and the cells were allowed to grow overnight. The cells were washed and dissociated from the plate with PBS containing 0.5 mM EDTA. Cellular cAMP content was measured by centrifuging the cell suspension at 150 g x 10 min. And resuspending the cells in a Hanks buffered salt solution at a density of 0.2 x 10 cells/ml. The cells were preincubated at room temperature for 15 min. and then incubated with 10 μM prostaglandin I2 (PGI2) and the indicated compound for an additional 10 min. Basal cAMP levels were determined by incubating the cells in 0.1% DMSO. The incubations were terminated by the addition of HCl (0.1 N final) and the cells measured for cAMP as described below.
Determinations of whole-cell cAMP content were performed by incubating 100 μl reconstituted rabbit anti-succinyl cAMP serum with 100 μl of the whole-cell reaction or known cAMP standard and 30 pmol of 125I-cAMP TME in a ScintiStrip™ well (300 μl final volume) at room temperature for 18 h. Total cpm (B0) was determined in the absence of sample of cAMP standard. The reaction mixture was then aspirated out of the well, and the individual wells were counted in a Beckman LS 6000SC with the window open from 10-999 for 1 min. The data were expressed as %B/B0 = [(standard or sample cpm - non-specific cpm) / (B0 cpm - non-specific cpm)] x 100. Non-specific cpm were determined by incubating only the 125I-cAMP TME with assay buffer (50 nM acetate; pH 5.8) in the ScintiStrip well. All determinations were performed in triplicate.
The Elevation of cAMP in Leukocytes
The effect of compounds of the invention on intracellular cAMP was investigated using human neutrophils or guinea pig eosinophils. Human neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B and the test compound for 10 min and then stimulated with FMLP. Guinea pig eosinophils were harvested by peritoneal lavage of animals previously treated with intra- peritoneal injections of human serum. Eosinophils were separated from the peritoneal exudate and incubated with isoprenaline and test compound. With both cell types, suspensions were centrifuged at the end of the incubation, the cell pellets were resuspended in buffer and boiled for 10 min prior to measurement of cAMP by specific radioimmunoassay (DuPont).
The most potent compounds according to the invention induced a concentration-dependent elevation of cAMP in neutrophils and/or eosinophils at concentrations of O.lnM to lμM. Human Whole Blood Assay Fresh blood was collected in heparinized tubes by venipuncture from healthy volunteers. These subjects had no apparent inflammatory conditions and had not taken any NSAIDs for at least 4 days prior to blood collection. Five hundred μL aliquots of human blood were initially pre-incubated at 37°C with either 2 μL DMSO (vehicle) or 2 μL of a test compound at a final concentration of up to 100 μM. Fifteen min later, the blood was incubated with lipopolysaccharide (LPS) at 1 μg/ml (Sigma Chem, #L-2630 from E. coli, serotype 0111:B4; diluted in 0.1% w/v BSA/PBS) for 24 h at 37°C. At the end of the 24 h incubation, the blood was further incubated with an additional amount of LPS (final concentration: 1 μg/ml) for 30 min at 37°C. This was followed by incubation with n-formyl-Met-Leu-Phe (f-MLP) at 1 μM (Sigma Chem, F- 3506, diluted in 1% w/v BSA/PBS) for 15 min at 37°C. The blood was immediately centrifuged at 4°C for 10 min. at 3,300 rpms to obtain plasma. A plasma aliquot was diluted in PBS and assayed for TNF-α using a commercial ELISA kit (Cistron). An additional plasma aliquot was de-proteinized with methanol and the supernatant was assayed for LTB4 using a commercial EIA kit (Cayman).
The instant compounds showed IC50 values ranging from 1 nM to 5 μM.
Human Mononuclear Cell Assay
Fresh blood was collected from healthy volunteers by venipuncture into tubes containing 0.13M sodium citrate as anticoagulant (final 10%v/v in blood). The blood was diluted in equal parts with PBS and gently layered on top of one half volume histopaque (1.077 density) and was centrifuged at 1400 rpm for 35 min at room temperature. After centrifugation, a distinct layer of mononuclear cells (monocytes and lymphocytes) located between the blood and histopaque layers could be aspirated off using a transfer pipette. The mononuclear cells were washed in calcium and magnesium free PBS. The cell pellet was resuspended in RPMI 1640 (Gibco BRL) complete media (containing streptomycin/penicillin and HEPES buffer) at a cell density of 1 x 106 cells/ml. Two hundred μl aliquots of mononuclear cells were mixed with 2 μl of DMSO (vehicle) or a test compound at a final concentration of up to 10 μM in the presence of 1% or 25% heat-inactivated human serum. Fifteen min. later, the cells were incubated with LPS at a final concentration of 1 μg/ml at 37°C for 20 h. At the end of the incubation period, the supernatant was obtained by centrifugation at 1000 rpm for 10 min and was assayed for TNF-α using a commercial ELISA kit (Cistron).
The instant compounds showed IC50 values ranging from 0.1 nM to 5 μM.
In Vivo inhibition of allergen induced bronchoconstriction Guinea pigs, 200 g, are sensitized with a lOOμg/ml ovalbumin in an A1203 suspension in physiological saline. Five hundred μl of this solution are injected mtraperitoneally and another 500 μl are injected in 6 ganglionic regions ( ±75 μl/ site). The animals are then housed for 4 to 6 weeks. Thirty minutes prior to the experimentation, the guinea pigs are treated with the test compound or vehicle and with mepyramine maleate, 1 mg/kg. The injection volume is 1 ml/kg of body weight.
After pre-treatment, the animals are placed in a whole body plethysmograph for conscious unrestrained guinea pigs. The animals are challenged for one minute with an aerosol containing ovalbumin in a concentration of 1% in physiological saline. The changes in pulmonary function assessed as changes in enhanced pause or Penh. Penh, a marker of bronchoconstriction, is defined as follows: Penh=[(expiratory time I relaxation time)-l]*[(peak expiratory flow I peak inspiratory flow] The results are expressed as the percentage of inhibition of the Penh increase versus the response obtained in a control experiment.
SPA based PDE activity assay protocol for measuring inhibition of Phosphodiesterase activity
Compounds which inhibit the hydrolysis of cAMP to AMP by the type-IV cAMP-specific phosphodiesterases were screened in 96- well plate format as follows:
In a 96 well-plate at 30 °C was added the test compound (dissolved in 2 ul DMSO), 188 μl of substrate buffer containing [2,8-3H] adenosine 3',5'-cyclic phosphate (cAMP, 100 nM), 10 mM MgCl2, 1 mM
EDTA, 50 mM Tris, pH 7.5. The reaction was initiated by the addition of 10 μl of human recombinant PDE-rV isozymes, either expressed and purified from sf9 cells, or from CHO-Kl cells (the amount was controlled so that ~ 10% product was formed in 10 min. at 30 °C). The reaction was stopped after 10 min. by the addition of 1 mg of PDE-SPA beads (Amersham). The product AMP generated was quantified on a Microbeta 96-well plate counter. The signal in the absence of enzyme was defined as the background. 100% activity was defined as the signal detected in the presence of enzyme and DMSO with the background subtracted. Percentage of inhibition was calculated accordingly. The IC50 value was approximated by the non-linear regression fitting of a ten point titration using the standard 4 parameter equation.
IC50 values were determined with 100 nM cAMP using the purified GST fusion protein of the human recombinant phosphodiesterase IVa (met-248) produced from a baculovirus/Sf-9 expression system. The instant compounds were shown to have IC50 values of 0.01 to 1000 nM.

Claims

WHAT IS CLAIMED IS:
1. A compound of Formula I
or a pharmaceutically acceptable salt thereof wherein:
Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Ci-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) C╬╣_3alkoxy, c) Ci-3alkylthio, d) Ci-3alkylsulfinyl, e) C 1-3 alkylsulfonyl, f) Ci-3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -C╬╕2C╬╣_3alkyl, k) -CH=CH-C(Me)2╬╕H,
n) tetrazol-5-yl, or o) -CH=N-0-CH2C02H; R1 is selected from: a) hydrogen, b) Ci-3alkyl, optionally substituted with -OH, or c) -Xl-Yl-Ar2, wherein: χ! _s 1) -CH2-, or
2) a bond; Y1 is 1) -O- 2) -S-, 3) -NR8-, or
4) a bond; Ar2 is an aromatic ring selected from phenyl, naphthyl, pyrimidinyl, pyridinyl or thienyl, optionally substituted with up to two substituents chosen independently among: 1) Cl-╬▓alkyl,
2) Cl-6alkoxy,
3) -OH,
4) halo, or
5) CF3;
ΗA is selected from: a) hydrogen or b) Ci-3alkyl.
R3 is selected from phenyl, naphthyl, pyridinyl, furyl, thienyl, or ethinyl, optionally substituted with up to two substituents chosen independently among: a) Ci-3 alkyl, b) Ci-3fluoroalkyl, c) C 1-6 alkoxy, d) Ci-3fluoroalkoxy, e) C i-3 alkylthio, f) halo, g) -OH, h) -N02, i) -CH2OH, j) -NHCONR9R10, k) -S(0) NRl1R12,
1) -SCH2(l,l-c-Pr)CH2C02H, m) 1-piperazinyl, optionally substituted with C1-3 alkyl, n) 4-morpholinyl, or o) -X2-Y2-Ar3, wherein,
X2 is D -CH2-, 2) -C(=NOH)-, or
3) a bond; Y is 1) -0-,
2) -S-, or
3) a bond; Ar3 is phenyl, pyridinyl, pyrimidinyl or pyrazinyl, optionally substituted with up to two substituents chosen independently among:
1) Ci-3alkyl, optionally substituted with -OH, or
2) -CH2CO2H. R4 and R0^ are independently selected from: a) hydrogen, b) Ci-3alkyl, c) -S(0)2Ci_3alkyl, or d) -S(0)2phenyl, optionally mono-substituted with Ci-3alkyl, C╬╣_3alkoxy, Ci-3alkylthio or halo.
R" and R^ are independently chosen from among: a) hydrogen, b) C1.4alkyl, c) -CO-C^alkyl, or d) -CO-phenyl, optionally mono-substituted with Ci galkyl,
Ci-3alkoxy, C╬╣_3alkylthio or halo; R┬░ is chosen from among: a) hydrogen, or b) Ci-5alkyl;
R9 and R^O are independently chosen from among: a)hydrogen, b) Ci-4alkyl, or c) phenyl; and
RU and Ε - are independently chosen from among: a) hydrogen or b) Ci-5alkyl.
2. A compound according to Claim 1 wherein:
Ri is selected from : a) Ci-3alkyl, optionally substituted with -OH, or W -Xi-Yi-Ar ;
R2 is hydrogen; and the remaining substituents are defined as in Claim 1.
3. A compound according to Claim 1 wherein:
-Xi-Y1- is -CH2-S-, and the remaining substituents are defined as in Claim 1.
4. A compound according to Claim 1 wherein: Ar2 is pyrimidinyl, optionally substituted with up to two substituents chosen independently among:
1) Cl-6alkyl, 2) Ci-6alkoxy,
3) -OH, or
4) halo, and the remaining substituents are defined as in Claim 1.
5. A compound according to Claim 1 wherein
Ar* is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Ci-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) Ci-3alkoxy, c) Ci-3alkylthio, d) Ci-3alkylsulfinyl, e) Ci-3alkylsulfonyl, f) Ci-3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -CO2H, j) -C╬╕2Ci-3alkyl,
Ri is selected from: b) Ci-3alkyl, optionally substituted with -OH, or c) -Xl-Yl-Ar , wherein: X1 is 1) -CH2-, or
2) a bond; Yl is 1) -O-
2) -S-,
3) -NR8-, or 4) a bond; Ar is pyrimidinyl optionally substituted with up to two substituents chosen independently among:
1) Ci-╬▓alkyl,
2) Ci-6alkoxy, 3) -OH, or
4) halo,
R2 is selected from: a) hydrogen or
R3 is selected from phenyl, naphthyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) Ci-3 alkyl, b) C i-3 fluoroalkyl, c) C i-6 alkoxy, d) Ci-3_luoroalkoxy, e) Ci-3 alkylthio, f) halo, g) -OH, h) -N02, i) -CH2OH, j) -NHCONR9R!0, k) -S(0)2NRllRl2, 1) -SCH2(l,l-c-Pr)CH2C02H or m) -X -╬│2-Ar3, wherein,
X2 is 1) -CH -,
2) -C(=NOH)-, or 3) a bond;
Y is 1) -0-,
2) -S-, or
3) a bond; Ar3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among:
1) Cl-3alkyl, optionally substituted with -OH, or
2) -CH2CO2H. R and R^ are independently selected from: a) hydrogen, b) Ci_3alkyl, c) -S(0)2Ci-3alkyl, or
R6 and R^ are independently chosen from among: a) hydrogen, b) C^alkyl, c) -CO-C1_4alkyl, or
R┬░ is chosen from among: a) hydrogen, or b) Ci-5alkyl;
R9 and R^-O are independently chosen from among: a)hydrogen, b) Ci-4alkyl, and
RU and Rl2 are independently chosen from among: a) hydrogen or b) Ci-5alkyl.
6. A compound according to Claim 1 wherein
Arl is an aromatic ring selected from phenyl, quinolinyl, pyridinyl, furyl, thienyl or thiazolyl, optionally substituted with up to two substituents chosen independently from among: a) Ci-6alkyl, optionally substituted with -OH, -CO2H, CO2C1- 3alkyl, and CN, b) Ci-3alkoxy, c) Ci-3alkylthio, d) Ci_3alkylsulfinyl, e) Ci-3alkylsulfonyl, f) Ci-3fluoroalkyl, optionally substituted with -OH, g) halo, h) -OH, i) -C02H, j) -C╬╕2Ci-3alkyl,
Ri is selected from: b) Ci-3alkyl, optionally substituted with -OH, or c) -X1-Y1-Ar , wherein:
Xl-Yl is CH2S;
Ar2 is pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) Ci-6alkyl,
2) C╬╣_6alkoxy,
3) -OH, or
4) halo,
R2 is hydrogen;
R3 is selected from phenyl, pyridinyl, furyl, or thienyl, optionally substituted with up to two substituents chosen independently among: a) C i-3 alkyl, b) Ci-3fluoroalkyl, c) C i-6 alkoxy, d) C╬╣_3_luoroalkoxy, e) C i-3 alkylthio, f) halo, g) -OH, h) -N02, i) -CH2OH, j) -NHCONR9R10, k) -X2-Y2-Ar3, wherein,
X2 is 1) -CH2-, or
2) a bond; Y2 is 1) -O-, 2) -S-, or
3) a bond;
Ar3 is phenyl, pyridinyl, or pyrimidinyl optionally substituted with up to two substituents chosen independently among: 1) Ci-3alkyl, optionally substituted with -OH, or
2) -CH2CO2H. R4 and R^ are independently selected from: a) hydrogen, b) Ci_3alkyl,
R6 and R^ are independently chosen from among: a) hydrogen, b) C^alkyl,
RS* RU and Rl2 are chosen from among: a) hydrogen, or b) Cl-5alkyl; and
R9 and R^-0 are independently chosen from among: a)hydrogen, b) Ci-4alkyl.
7. A compound according to Claim 1 selected from the group consisting of
8. A pharmaceutical composition for treating asthma comprising a non- toxic therapeutically effective amount of a compound according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition for treating a phosphodiesterase IV mediated disease by increasing the cellular level of cAMP, comprising a non-toxic therapeutically effective amount of a compound according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier.
10. A method of treating asthma comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.
11. A method of treating a phosphodiesterase IV mediated disease by inhibiting PDE IV comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 1.
12. An anti-asthma pharmaceutical formulation comprising an acceptable, non-toxic, therapeutically effective amount of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5, 6 or 7, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
13. A phosphodiesterase IV inhibitor pharmaceutical composition comprising an acceptable phosphodiesterase IV inhibiting amount, effective to increase the cellular level of cAMP, of a compound of formula (I), as defined in claim 1, 2, 3, 4, 5, 6 or 7, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
14. A compound of formula (I), as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in the treatment of asthma.
15. Use of a compound of formula (I), as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treating a phosphodiesterase IV mediated disease by increasing the cellular level of cAMP.
16. Use of a compound of formula (I), as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof as a phosphodiesterase IV inhibitor.
EP98946190A 1997-10-03 1998-10-01 Aryl thiophene derivatives as pde iv inhibitors Withdrawn EP1019399A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6091497P 1997-10-03 1997-10-03
US60914P 1997-10-03
GBGB9808109.4A GB9808109D0 (en) 1998-04-16 1998-04-16 Aryl thiophene derivatives as pde iv inhibitors
GB9808109 1998-04-16
PCT/CA1998/000931 WO1999018099A1 (en) 1997-10-03 1998-10-01 Aryl thiophene derivatives as pde iv inhibitors

Publications (1)

Publication Number Publication Date
EP1019399A1 true EP1019399A1 (en) 2000-07-19

Family

ID=26313480

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98946190A Withdrawn EP1019399A1 (en) 1997-10-03 1998-10-01 Aryl thiophene derivatives as pde iv inhibitors

Country Status (5)

Country Link
EP (1) EP1019399A1 (en)
JP (1) JP3409029B2 (en)
AU (1) AU732406B2 (en)
CA (1) CA2305414A1 (en)
WO (1) WO1999018099A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002226464A (en) * 2001-01-30 2002-08-14 Sumitomo Pharmaceut Co Ltd Triaryl analogue and its use
ATE339416T1 (en) * 2001-04-13 2006-10-15 Vertex Pharma INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
CA2461363A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
JP4331951B2 (en) * 2002-08-30 2009-09-16 富士フイルム株式会社 Novel compound and optical element using the same
CN101039936A (en) 2004-08-23 2007-09-19 惠氏公司 Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
CN101429189B (en) * 2008-12-24 2014-07-23 沈阳药科大学 2,3-disubstituted aryl thiophene derivants and uses thereof
TWI476195B (en) * 2009-05-26 2015-03-11 Abbvie Bahamas Ltd Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG192677A1 (en) * 2011-02-07 2013-09-30 Scipharm Sarl Novel composition for the treatment of cystic fibrosis
CA3122383A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
MX2016001602A (en) 2013-08-08 2016-12-15 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3531497A (en) * 1967-02-21 1970-09-29 Upjohn Co 2,4,5 - triphenyl - (and substituted triphenyl) - 3 - acetonitriles of pyrrole
GB1271082A (en) * 1968-05-07 1972-04-19 Wyeth John & Brother Ltd Furan, pyrrole and thiophene derivatives
GB1381860A (en) * 1971-06-03 1975-01-29 Wyeth John & Brother Ltd Tetrazole derivatives
DE3873278T2 (en) * 1987-09-22 1993-02-25 Merck & Co Inc ARYL-SUBSTITUTED THIOPHEN-3-OLE, THEIR DERIVATIVES AND ANALOGS AS LIPOXYGENASE INHIBITORS.
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JPH06135961A (en) * 1992-10-23 1994-05-17 Nippon Iyakuhin Kogyo Kk New diphynelpyrrolylfuran derivative
FR2730996B1 (en) * 1995-02-23 1997-06-20 Adir NOVEL THIOPHENE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPH11228535A (en) * 1995-05-30 1999-08-24 Tsumura & Co New compound and anti-dermatitis agent
PT853083E (en) * 1997-01-06 2001-12-28 Pfizer COMPOSITION OF PYRIDILFURANE AND PYRIDYLTHOPHENE AND ITS PHARMACEUTICAL UTILIZATION

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9918099A1 *

Also Published As

Publication number Publication date
WO1999018099B1 (en) 1999-05-27
AU732406B2 (en) 2001-04-26
JP3409029B2 (en) 2003-05-19
WO1999018099A1 (en) 1999-04-15
AU9334798A (en) 1999-04-27
CA2305414A1 (en) 1999-04-15
JP2001519347A (en) 2001-10-23

Similar Documents

Publication Publication Date Title
US6034089A (en) Aryl thiophene derivatives as PDE IV inhibitors
US6020339A (en) Aryl furan derivatives as PDE IV inhibitors
US5710170A (en) Tri-aryl ethane derivatives as PDE IV inhibitors
US5710160A (en) Diphenyl pyridyl ethane derivatives as PDE IV inhibitors
US5698584A (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors
USRE47142E1 (en) Compounds and methods for treating inflammatory and fibrotic disorders
US10730863B2 (en) Bridged bicyclic compounds as farnesoid X receptor modulators
US6204275B1 (en) PDE IV inhibiting compounds, compositions and methods of treatment
JP3337477B2 (en) 3,4-Diaryl-2-hydroxy-2,5-dihydrofuran as prodrug of COX-2 inhibitor
US6316472B1 (en) Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6057319A (en) 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
JP3465825B2 (en) Triarylethane derivatives as PDE IV IV inhibitors
EP1019399A1 (en) Aryl thiophene derivatives as pde iv inhibitors
US6200993B1 (en) Heterosubstituted pyridine derivatives as PDE4 inhibitors
US6180650B1 (en) Heterosubstituted pyridine derivatives as PDE 4 inhibitors
JPH10508587A (en) Bisarylcarbinol cinnamic acids as leukotriene biosynthesis inhibitors
CN101679191A (en) Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them
CA2239053C (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000503

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000503;LT PAYMENT 20000503;LV PAYMENT 20000503;MK PAYMENT 20000503;RO PAYMENT 20000503;SI PAYMENT 20000503

17Q First examination report despatched

Effective date: 20010301

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020625